

Practitioner's Docket No. U 012653-9

## CHAPTER II

TRANSMITTAL LETTER  
TO THE UNITED STATES ELECTED OFFICE (EO/US)

## (ENTRY INTO U.S. NATIONAL PHASE UNDER CHAPTER II)

PCT/FI98/00749	23 SEPT. 1998	23 SEPT. 1997
INTERNATIONAL APPLICATION NO. CLAIMED	INTERNATIONAL FILING DATE	PRIORITY DATE

NOVEL GENE DEFECTIVE IN APECED AND ITS USE  
TITLE OF INVENTION

Kai KROHN; Maarit HEINO; Part PETERSON; Hamish SCOTT; Stylianos ANTONARAKIS; Maria  
LALIOTI; Nobuyoshi SHIMIZU; Jan KUDOH  
APPLICANT(S)

Box PCT  
Assistant Commissioner for Patents  
Washington D.C. 20231  
ATTENTION: EO/US

NOTE: The completion of those filing requirements that can be made at a time later than 30 months from the priority date results from the Commissioner exercising his judgment under the authority granted under 35 USC 371(d). The filing receipt will show the actual date of receipt of the last item completing the entry into the national phase. See 37 C.F.R. §1.491 which states: "An international application enters the national state when the applicant has filed the documents and fees required by 35 USC 371(c) within the periods set forth in § 1.494 and § 1.495."

## CERTIFICATION UNDER 37 C.F.R. 1.10\*

(Express Mail label number is **mandatory**.)

(Express Mail certification is optional.)

I hereby certify that this correspondence and the documents referred to as attached therein are being deposited with the United States Postal Service on this date MARCH 14, 2000, in an envelope as "Express Mail Post Office to Addressee," Mailing Label Number EL386267956US, addressed to the: Assistant Commissioner for Patents, Washington, D.C. 20231.

JENNIFER RASHKIN

(type or print name of person mailing paper)

Signature of person mailing paper

**WARNING:** Certificate of mailing (first class) or facsimile transmission procedures of 37 C.F.R. 1.8 cannot be used to obtain a date of mailing or transmission for this correspondence.

**\*WARNING:** Each paper or fee filed by "Express Mail" **must** have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. 1.10(b).  
"Since the filing of correspondence under § 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will **not** be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

(Transmittal Letter to the United States Elected Office (EO/US)—page 1 of 8)

EL3.8 6 2 6 7 9 5 6 US

**WARNING:** *Where the items are those which can be submitted to complete the entry of the international application into the national phase are subsequent to 30 months from the priority date the application is still considered to be in the international state and if mailing procedures are utilized to obtain a date the express mail procedure of 37 C.F.R. §1.10 must be used (since international application papers are not covered by an ordinary certificate of mailing - See 37 C.F.R. §1.8.*

**NOTE:** *Documents and fees must be clearly identified as a submission to enter the national state under 35 USC 371 otherwise the submission will be considered as being made under 35 USC 111. 37 C.F.R. § 1.494(f).*

1. Applicant herewith submits to the United States Elected Office (EO/US) the following items under 35 U.S.C. 371:
  - a. ☒ This express request to immediately begin national examination procedures (35 U.S.C. 371(f)).
  - b. ☒ The U.S. National Fee (35 U.S.C. 371(c)(1)) and other fees (37 C.F.R. § 1.492) as indicated below:

2.Fees

CLAIMS FEE	(1) FOR	(2) NUMBER FILED	(3) NUMBER EXTRA	(4) RATE	(5) CALCULATIONS	
[ ]*	TOTAL CLAIMS	24 - 20 =	4	x \$ 18.00 =	\$72.00	
	INDEPENDENT CLAIMS	4 - 3 =	1	x \$ 78.00 =	78.00	
	MULTIPLE DEPENDENT CLAIM(S) (if applicable) + \$260.00					
BASIC FEE**	<p>[ ] U.S. PTO WAS INTERNATIONAL PRELIMINARY EXAMINATION AUTHORITY Where an International preliminary examination fee as set forth in § 1.482 has been paid on the international application to the U.S. PTO:</p> <p>[ ] and the international preliminary examination report states that the criteria of novelty, inventive step (non-obviousness) and industrial activity, as defined in PCT Article 33(2) to (4) have been satisfied for all the claims presented in the application entering the national stage (37 CFR 1.492(a)(4)) ..... \$96.00</p> <p>[ ] and the above requirements are not met (37 CFR 1.492(a)(1)) ..... \$670.00</p> <p>[X] U.S. PTO WAS NOT INTERNATIONAL PRELIMINARY EXAMINATION AUTHORITY Where no international preliminary examination fee as set forth in § 1.482 has been paid to the U.S. PTO, and payment of an international search fee as set forth in § 1.445(a)(2) to the U.S. PTO:</p> <p>[ ] has been paid (37 CFR 1.492(a)(2)) ..... \$690.00</p> <p>[X] has not been paid (37 CFR 1.492(a)(3)) ..... \$970.00</p> <p>[ ] where a search report on the international application has been prepared by the European Patent Office or the Japanese Patent Office (37 CFR 1.492(a)(5)) ..... \$840.00</p>					
	Total of above Calculations					= \$1,120.00
SMALL ENTITY	Reduction by ½ for filing by small entity, if applicable. Affidavit must be filed. (note 37 CFR 1.9, 1.27, 1.28)					-
	Subtotal					
	Total National Fee					\$
	Fee for recording the enclosed assignment document \$40.00 (37 CFR 1.21(h)). (See Item 13 below). See attached "ASSIGNMENT COVER SHEET".					
TOTAL	Total Fees enclosed					\$1,120.00

\*See attached Preliminary Amendment Reducing the Number of Claims.

- i. ☒ A check in the amount of \$1,120.00 to cover the above fees is enclosed.  
ii. ☐ Please charge Account No. \_\_\_\_\_ in the amount of \$ \_\_\_\_\_.  
A duplicate copy of this sheet is enclosed.

**\*\*WARNING:** "To avoid abandonment of the application the applicant shall furnish to the United States Patent and Trademark Office not later than the expiration of 30 months from the priority date: \* \* \* (2) the basic national fee (see § 1.492(a)) The 30-month time limit may not be extended." 37 C.F.R. § 1.495(b).

**WARNING:** If the translation of the international application and/or the oath or declaration have not been submitted by the applicant within thirty (30) months from the priority date, such requirements may be met within a time period set by the Office. 37 C.F.R. § 1.495(b)(2). The payment of the surcharge set forth in § 1.492(e) is required as a condition for accepting the oath or declaration later than thirty (30) months after the priority date. The payment of the processing fee set forth in § 1.492(f) is required for acceptance of an English translation later than thirty (30) months after the priority date. Failure to comply with these requirements will result in abandonment of the application. The provisions of § 1.136 apply to the period which is set. Notice of Jan. 3, 1993, 1147 O.G. 29 to 40.

3. ☒ A copy of the International application as filed (35 U.S.C. 371(c)(2)):

**NOTE:** Section 1.495 (b) was amended to require that the basic national fee and a copy of the international application must be filed with the Office by 30 months from the priority date to avoid abandonment "The International Bureau normally provides the copy of the international application to the Office in accordance with PCT Article 20. At the same time, the International Bureau notifies applicant of the communication to the Office. In accordance with PCT Rule 47.1, that notice shall be accepted by all designated offices as conclusive evidence that the communication has duly taken place. Thus, if the applicant desires to enter the national stage, the applicant normally need only check to be sure the notice from the International Bureau has been received and then pay the basic national fee by 30 months from the priority date." Notice of Jan. 7, 1993, 1147 O.G. 29 to 40, at 35-36. See item 14c below.

- a. ☐ is transmitted herewith.  
b. ☐ is not required, as the application was filed with the United States Receiving Office.  
c. ☒ has been transmitted  
i. ☒ by the International Bureau.  
Date of mailing of the application (from form PCT/IB/308): APRIL 1, 1999.  
ii. ☐ by applicant on \_\_\_\_\_.  
Date

4. ☒ A translation of the International application into the English language (35 U.S.C. 371(c)(2)):

- a. ☒ is transmitted herewith.  
b. ☐ is not required as the application was filed in English.  
c. ☐ was previously transmitted by applicant on \_\_\_\_\_.  
Date  
d. ☐ will follow.

09508658 14 MAR 2000

5. [X] Amendments to the claims of the International application under PCT Article 19 (35 U.S.C. 371(c)(3)):

NOTE: The Notice of January 7, 1993 points out that 37 C.F.R. § 1.495(a) was amended to clarify the existing and continuing practice that PCT Article 19 amendments must be submitted by 30 months from the priority date and this deadline may not be extended. The Notice further advises that: "The failure to do so will not result in loss of the subject matter of the PCT Article 19 amendments. Applicant may submit that subject matter in a preliminary amendment filed under section 1.121. In many cases, filing an amendment under section 1.121 is preferable since grammatical or idiomatic errors may be corrected." 1147 O.G. 29-40, at 36.

- a. ☐ are transmitted herewith.
- b. ☐ have been transmitted
- i. ☐ by the International Bureau.  
Date of mailing of the amendment (from form PCT/IB/308): \_\_\_\_\_.
- ii. ☐ by applicant on \_\_\_\_\_.  
Date
- c. ☒ have not been transmitted as
- i. ☒ applicant chose not to make amendments under PCT Article 19.  
Date of mailing of Search Report (from form PCT/ISA/210): JAN. 25, 1999.
- ii. ☐ the time limit for the submission of amendments has not yet expired.  
The amendments or a statement that amendments have not been made will be transmitted before the expiration of the time limit under PCT Rule 46.1.

6. ☒ A translation of the amendments to the claims under PCT Article 19 (38 U.S.C. 371(c)(3)):
- a. ☐ is transmitted herewith.
- b. ☐ is not required as the amendments were made in the English language.
- c. ☒ has not been transmitted for reasons indicated at point 5(c) above.
7. ☒ A copy of the international examination report (PCT/IPEA/409)
- ☒ is transmitted herewith.
- ☐ is not required as the application was filed with the United States Receiving Office.
8. ☒ Annex(es) to the international preliminary examination report
- a. ☒ is/are transmitted herewith.
- b. ☐ is/are not required as the application was filed with the United States Receiving Office.
9. ☒ A translation of the annexes to the international preliminary examination report
- a. ☐ is transmitted herewith.
- b. ☒ is not required as the annexes are in the English language.

10. ☒ An oath or declaration of the inventor (35 U.S.C. 371(c)(4)) complying with 35 U.S.C. 115
- a. ☐ was previously submitted by applicant on \_\_\_\_\_.  
Date
- b. ☐ is submitted herewith, and such oath or declaration
- i. ☐ is attached to the application.
- ii. ☐ identifies the application and any amendments under PCT Article 19 that were transmitted as stated in points 3(b) or 3(c) and 5(b); and states that they were reviewed by the inventor as required by 37 C.F.R. 1.70.
- c. ☒ will follow.

Other document(s) or information included:

11. ☒ An International Search Report (PCT/ISA/210) or Declaration under PCT Article 17(2)(a):
- a. ☒ is transmitted herewith.
- b. ☐ has been transmitted by the International Bureau.  
Date of mailing (from form PCT/IB/308): \_\_\_\_\_.
- c. ☐ is not required, as the application was searched by the United States International Searching Authority.
- d. ☐ will be transmitted promptly upon request.
- e. ☐ has been submitted by applicant on \_\_\_\_\_.  
Date
12. ☒ An Information Disclosure Statement under 37 C.F.R. 1.97 and 1.98:
- a. ☒ is transmitted herewith.  
Also transmitted herewith is/are:  
☒ Form PTO-1449 (PTO/SB/08A and 08B).  
☒ Copies of citations listed.
- b. ☐ will be transmitted within THREE MONTHS of the date of submission of requirements under 35 U.S.C. 371(c).
- c. ☐ was previously submitted by applicant on \_\_\_\_\_.  
Date
13. ☐ An assignment document is transmitted herewith for recording.

A separate ☐ "COVER SHEET FOR ASSIGNMENT (DOCUMENT) ACCOMPANYING NEW PATENT APPLICATION" or ☐ FORM PTO 1595 is also attached.

\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_

14. ☒ Additional documents:
- a. ☒ Copy of request (PCT/RO/101)
- b. ☒ International Publication No. WO99/15559
- i. ☐ Specification, claims and drawing
- ii. ☒ Front page only
- c. ☒ Preliminary amendment (37 C.F.R. § 1.121)
- d. ☒ Other

Form PCT/IB/306; Form PCT/IB/308; Form PCT/IB/332

---



---

15. ☒ The above checked items are being transmitted
- a. ☒ before 30 months from any claimed priority date.
- b. ☐ after 30 months.
16. ☐ Certain requirements under 35 U.S.C. 371 were previously submitted by the applicant on \_\_\_\_\_, namely:
- 
- 
- 

#### AUTHORIZATION TO CHARGE ADDITIONAL FEES

**WARNING:** *Accurately count claims, especially multiple dependent claims, to avoid unexpected high charges if extra claims are authorized.*

**NOTE:** *"A written request may be submitted in an application that is an authorization to treat any concurrent or future reply, requiring a petition for an extension of time under this paragraph for its timely submission, as incorporating a petition for extension of time for the appropriate length of time. An authorization to charge all required fees, fees under § 1.17, or all required extension of time fees will be treated as a constructive petition for an extension of time in any concurrent or future reply requiring a petition for an extension of time under this paragraph for its timely submission. Submission of the fee set forth in § 1.17(a) will also be treated as a constructive petition for an extension of time in any concurrent reply requiring a petition for an extension of time under this paragraph for its timely submission." 37 C.F.R. § 1.136(a)(3).*

**NOTE:** *"Amounts of twenty-five dollars or less will not be returned unless specifically requested within a reasonable time, nor will the payer be notified of such amounts; amounts over twenty-five dollars may be returned by check or, if requested, by credit to a deposit account." 37 C.F.R. § 1.126(a).*

- ☒ The Commissioner is hereby authorized to charge the following additional fees that may be required by this paper and during the entire pendency of this application to Account No. 12-0425.

☒ 37 C.F.R. 1.492(a)(1), (2), (3), and (4) (filing fees)

**WARNING:** *Because failure to pay the national fee within 30 months without extension (37 C.F.R. § 1.495(b)(2)) results in abandonment of the application, it would be best to always check the above box.*

☐ 37 C.F.R. 1.492(b), (c) and (d) (presentation of extra claims)

**NOTE:** *Because additional fees for excess or multiple dependent claims not paid on filing or on later presentation must*

only be paid or these claims cancelled by amendment prior to the expiration of the time period set for response by the PTO in any notice of fee deficiency (37 C.F.R. § 1.492(d)), it might be best not to authorize the PTO to charge additional claim fees, except possible when dealing with amendments after final action.

- ☒ 37 C.F.R. 1.17 (application processing fees)
- ☒ 37 C.F.R. 1.17(a)(1)-(5)(extension fees pursuant to § 1.136(a).
- ☒ 37 C.F.R. 1.18 (issue fee at or before mailing of Notice of Allowance, pursuant to 37 C.F.R. 1.311(b))

NOTE: Where an authorization to charge the issue fee to a deposit account has been filed before the mailing of a Notice of Allowance, the issue fee will be automatically charged to the deposit account at the time of mailing the notice of allowance. 37 C.F.R. § 1.311(b).

NOTE: 37 C.F.R. 1.28(b) requires "Notification of any change in loss of entitlement to small entity status must be filed in the application . . . prior to paying, or at the time of paying . . . issue fee." From the wording of 37 C.F.R. § 1.28(b): (a) notification of change of status must be made even if the fee is paid as "other than a small entity" and (b) no notification is required if the change is to another small entity.

- ☒ 37 C.F.R. § 1.492(e) and (f) (surcharge fees for filing the declaration and/or filing an English translation of an International Application later than 30 months after the priority date).

  
SIGNATURE OF PRACTITIONER

William R. Evans

(type or print name of practitioner)

c/o Ladas & Parry

26 West 61<sup>st</sup> Street

P.O. Address

New York, NY 10023

Reg. No.: 25,858

Tel. No.: (212) 708-1930

Customer No.:

09508658 140300



03 Rec'd PCT/PTO 14 MAR 2000

**PATENT**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

PCT/F198/00749                      23 SEPT. 1998                      23 SEPT. 1997  
INT'L APPLICATION NO.              INT'L FILING DATE              PRIORITY DATE CLAIMED

NOVEL GENE DEFECTIVE IN APECED AND ITS USE  
TITLE OF INVENTION

Kai KROHN; Maarit HEINO; Part PETERSON; Hamish SCOTT; Stylianos  
ANTONARAKIS; Maria LALIOTI; Nobuyoshi SHIMIZU; Jan KUDOH  
APPLICANT(S)

Attorney Docket: U 012653-9

Commissioner of Patents and Trademarks  
Washington, D.C. 20231

**PRELIMINARY AMENDMENT**

Please amend the above application as follows.

**In the Claims**

Claim 3, line 1, delete " or 2"

Claim 7, line 1, delete "or 6"


Claim 8, line 1, delete "any of claims 5 to 7" and substitute therefor  
-- claim 5--

**CERTIFICATION UNDER 37 C.F.R. 1.10\***  
(Express Mail label number is *mandatory*.)  
(Express Mail certification is *optional*.)

I hereby certify that this correspondence and the documents referred to as attached therein are being deposited with the United States Postal Service on this date MARCH 14, 2000 in an envelope as "Express Mail Post Office to Addressee," Mailing Label Number EL386267956US, addressed to the: Assistant Commissioner for Patents, Washington, D.C. 20231.

JENNIFER RASHKIN

(Type or print name of person mailing paper)

  
Signature of person mailing paper

**WARNING:**

Certificate of mailing (first class) or facsimile transmission procedures of 37 C.F.R. 1.8 cannot be used to obtain a date of mailing or transmission for this correspondence.

EL386267956US



Form B

**VERIFIED STATEMENT CLAIMING SMALL ENTITY STATUS**  
**(37 CFR 1.9(f) & 1.27(c))—SMALL BUSINESS CONCERN**

Docket Number (Optional)

Applicant or Patentee: Finnish Immunotechnology Ltd.  
 Serial or Patent No.: \_\_\_\_\_  
 Filed or Issued: \_\_\_\_\_  
 Title: Novel gene defective in apeced and its use

I hereby declare that I am

- ☐ the owner of the small business concern identified below;  
☒ an official of the small business concern empowered to act on behalf of the concern identified below:

NAME OF SMALL BUSINESS CONCERN Finnish Immunotechnology Ltd.  
 ADDRESS OF SMALL BUSINESS CONCERN Lenkkeilijätkatu 8, FIN-33530 Tampere, Finland

I hereby declare that the above identified small business concern qualifies as a small business concern as defined in 37 CFR 121.12, and reproduced in 37 CFR 1.9(d), for purposes of paying reduced fees to the United States Patent and Trademark Office, in that the number of employees of the concern, including those of its affiliates, does not exceed 500 persons. For purposes of this statement, (1) the number of employees of the business concern is the average over the previous fiscal year of the concern of the persons employed on a full-time, part-time or temporary basis during each of the pay periods of the fiscal year, and (2) concerns are affiliates of each other when either, directly or indirectly, one concern controls or has the power to control the other, or a third party or parties controls or has the power to control both.

I hereby declare that rights under contract or law have been conveyed to and remain with the small business concern identified above with regard to the invention described in:

- ☒ the specification filed herewith with title as listed above.  
☐ the application identified above.  
☐ the patent identified above.

If the rights held by the above identified small business concern are not exclusive, each individual, concern or organization having rights in the invention must file separate verified statements averring to their status as small entities, and no rights to the invention are held by any person, other than the inventor, who would not qualify as an independent inventor under 37 CFR 1.9(c) if that person made the invention, or by any concern which would not qualify as a small business concern under 37 CFR 1.9(d), or a nonprofit organization under 37 CFR 1.9(e).

Each person, concern or organization having any rights in the invention is listed below:

- ☐ no such person, concern, or organization exists.  
☐ each such person, concern or organization is listed below.

Separate verified statements are required from each named person, concern or organization having rights to the invention averring to their status as small entities. (37 CFR 1.27)

I acknowledge the duty to file, in this application or patent, notification of any change in status resulting in loss of entitlement to small entity status prior to paying, or at the time of paying, the earliest of the issue fee or any maintenance fee due after the date on which status as a small entity is no longer appropriate. (37 CFR 1.28(b))

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application, any patent issuing thereon, or any patent to which this verified statement is directed.

NAME OF PERSON SIGNING Pekka Sillanaukee  
 TITLE OF PERSON IF OTHER THAN OWNER chief executive officer  
 ADDRESS OF PERSON SIGNING Lenkkeilijätkatu 8, 33520 TAMPERE FINLAND  
 SIGNATURE [Signature] DATE March 7th, 2000

NOVEL GENE DEFECTIVE IN APECED AND ITS USE**Field of the invention**

The present invention relates to a novel gene, a novel protein encoded by said gene, a mutated form of the gene and to diagnostic and therapeutic uses of the gene or a mutated form thereof. More specifically, the present invention relates to a novel gene defective in autoimmune polyendocrinopathy syndrome type I (APS I), also called autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) (MIM No. 240,300).

**10 Background**

Autoimmune polyglandular syndrome type I (APS I), also known as autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED), is a rare recessively inherited disease (MIM No. 240,300) that is more prevalent among certain isolated populations, such as Finnish, Sardinian and Iranian Jewish populations. The incidence of the disease among the Finns and the Iranian Jews is estimated to be 1:25000 and 1:9000, respectively, whereas only few cases in other parts of the world are found each year.

APECED is one of the two major autoimmune polyendocrinopathy syndromes. The causing factor of APECED has not yet been identified. The syndrome is characterized by lack of tolerance to numerous self-antigens and can therefore be considered as a prototype of organ-specific autoimmune diseases. In APECED, the patient develops chronic mucocutaneous candidiasis soon after birth, and later several organ-specific autoimmune diseases, mainly hypoparathyroidism, Addison's disease, chronic atrophic gastritis with or without pernicious anemia, and in puberty gonadal dysfunction occur [Ahonen P, Clin. Genet. 27 (1985) 535-542]. An accepted criterion for diagnosis of APECED is the presence of at least two of the three main symptoms, Addison's disease, hypoparathyroidism and candidiasis, in patients [Neufeld, M. *et al.*, Medicine 60 (1981) 355-362]. Immunologically, the major findings are the presence of high-titer serum autoantibodies against the effected organs, antibodies against *Candida albicans*, and low or lacking T-cell responses toward candidal antigens [Blizzard, R. M. and Kyle M., J. Clin. Invest. 42 (1963) 1653-1660; Arulanantham, K. *et al.*, New Eng. J. Med. 300 (1979) 164-168; Krohn, K. *et al.*, Lancet 339 (1992) 770-773; Uibo R. *et al.*, J. Clin. Endocrinol. Metab. 78 (1994) 323-328]. The disease usually occurs in

childhood, but new tissue specific symptoms may appear throughout life [Ahonen, P. *et al.*, New Engl. J. Med. 322 (1990) 1829-1836]. APECED is not associated with a particular HLA haplotype, and both males and females are equally affected consistent with the autosomal recessive mode of inheritance.

5       The locus for the APECED gene has been mapped to chromosome 21q22.3 between gene markers D21S49 and D21S171 based on linkage analysis of Finnish families [Aaltonen, J. *et al.*, Nature Genet. 8 (1994) 83-87]. Recently, Börses *et al.* reported a maximum LOD score of 10.23 with marker D21S1912 just proximal to the gene PFKL, and thus by linkage disequilibrium  
10       studies the critical region for APECED can be considered to be less than 500 kb between markers D21S1912 and D21S171. Locus heterogeneity was not revealed by linkage analysis of non-Finnish families [Björnses, P. *et al.*, Am. J. Hum. Genet. 59 (1996) 879-886].

      For the APECED gene, the name "autoimmune regulator" or "AIRE"  
15       has been adopted by the scientific community after the priority date of the present application. Similarly the protein encoded by the AIRE gene is now called the "AIRE protein".

      Physical maps of human chromosome 21q22.3 have been developed using YACs, and bacterial based large insert cloning vectors  
20       [Chumakov *et al.*, Nature 359 (1992) 380; Stone *et al.*, Genome Res. 6 (1996) 218], and many laboratories have contributed to the construction of a transcription map of the whole chromosome and 21q22.3 in particular [Chen *et al.*, Genome Res. 6 (1996) 747-760; Yaspo *et al.*, Hum. Mol. Genet. 4 (1995) 1291-1304]. Numerous trapped exons from chromosome 21 specific cosmids  
25       and also physical contigs from the APECED critical region have been identified and partially characterized. In addition, a number of ESTs from the international human genome project have been mapped to the APECED critical region.

      Recently, as part of the international efforts of generating the entire  
30       sequence of human chromosome 21 and international agreements on the immediate availability of this type of sequence data, the partial sequence of the APECED gene critical region was made available in GenBank by the Stanford Human Genome Center which is currently carrying out the sequencing of 1.0 Mb around the critical region of the APECED gene.

35       However, the precise location and the sequence of the APECED gene and the nature of the gene product have not so far been clarified. Thus

at present the diagnosis of APECED is based mainly on developed clinical symptoms and typical clinical findings, e.g. the presence of autoantibodies against adrenal cortex or steroidogenic enzymes P450c17 and/or P450scc. The linkage analysis is seldom used. Further, means for natal or presymptomatic diagnosis of the disease are not easily available, since the linkage analysis provides only an indirect data through known gene markers and requires samples from several family members in several generations. Additionally, the linkage analysis is tedious and can be performed only in specialized laboratories by highly-skilled personnel.

Also the mapping of the carriers of the disease gene is presently based on the linkage analysis and thus not readily available.

### Summary of the invention

We have now identified a novel gene encoding a novel zinc finger protein, designated as autoimmune regulator 1 or AIR-1, which is mutated in APECED. The novel gene and protein allow further development of the diagnosis and therapy of diseases related to immune maturation and regulation of immune response towards self and nonself, such as APECED.

The object of the invention is to provide means which are useful in a diagnostic method and a gene therapeutic method in the diagnosis and treatment of diseases related to immune maturation and regulation of immune response towards self and nonself, such as APECED.

Another object of the invention is to provide a novel method for the diagnosis of diseases related to immune maturation and regulation of immune response towards self and nonself, such as APECED, including the pre- and postnatal diagnosis and the mapping of the carriers, the method being easy and reliable to perform.

The present invention relates to an isolated DNA sequence comprising the sequence id. no. 1 or a functional fragment or variant thereof, or a functionally equivalent isolated DNA sequence hybridizable thereto, the DNA sequence being associated with diseases related to immune maturation and regulation of immune response towards self and nonself, such as APECED. Preferably said isolated DNA sequence includes a gene defect responsible for APECED.

The present invention also relates to a protein comprising the amino acid sequence id. no. 2 or a functionally equivalent fragment or variant thereof, the protein being associated with diseases related to immune maturation and



DNA Res. 4 (1997) 45 -52] are indicated by horizontal lines. The APECED gene located just proximal to the 5' end of the neighboring gene PFKL is indicated by a solid arrow. N indicates *NotI* sites. DNA marker D21S1912 is shown as open box.

- 5 Figure 2 shows the structures of the APECED gene and AIR proteins. (A) Cloning strategy of APECED cDNAs and the order of the exons in the APECED gene. DNA fragments amplified by PCR and 3'- and 5'-RACE are indicated by the lines. Exon 1' is the 5'-noncoding exon of the AIR-2 and AIR-3. An additional alternative splicing of AIR-3 in exon 10, resulting in an amino acid change in its downstream, is indicated by vertical lines. Each exon, except exon 1', is bordered by the common splice site consensus sequence, ag:gt. Mutations in the exon 2 and exon 6 are indicated by the arrows.
- 10 (B) Schematic presentation of the three AIR proteins showing distinct structural motifs, including the PHD finger motif (PHD), the LXXLL motif (L), proline-rich region (PRR), and cystein-rich region (CRR).
- 15

- Figure 3 shows electropherograms showing the sequence surrounding the mutations in the APECED gene. (A) Mutation analysis of a Swiss APECED family. The parents are heterozygous for the allele (normal "C" and abnormal "T"). The affected boy and girl show the "C" to "T" transition resulting in the "Arg" to "Stop" nonsense mutation at amino acid position 257.
- 20 (B) Mutation analysis of two Finnish APECED patients. The patient MP is homozygous for the mutant allele (left), NP is heterozygous for the allele (right). (C) The patient NP shows the "A" to "G" transversion resulting in the "Lys" to "Glu" missense mutation at amino acid position 42. FLEB is a normal control.
- 25

- Figure 4 shows the result of a restriction enzyme *TaqI* digestion assay demonstrating the R257stop mutation. Four APECED patients [HP1 (lane 1), HP2 (lane 2), NP (lane 6), and MP (lane 8)], the mothers of two families [HM (lane 5) and NM (lane 7)], two healthy siblings [HN1 (lane 3) and HN2 (lane 4)] of family H and normal controls [C1, C2 and C3 (lanes 9-11)] are shown. The APECED patients HP1, HP2 and MP are homozygotes for the R257stop mutation. The APECED patient NP is heterozygous for the R257stop mutation but is carrying a mutation at a different position in another allele of the APECED gene (shown above in Fig. 3C). Both mothers (HM and NM) and two healthy siblings (HN1 and HN2) are heterozygous for the R257stop mutation and therefore carriers of APECED but are not having the
- 30
- 35





positive cell co-expresses a marker (CD83) typical for cells belonging to monocyte-macrophage-dendritic cell lineage.

Figure 9 shows the expression of the AIR protein, demonstrated by immunofluorescence, in mature, activated dendritic cells from peripheral blood.

- 5 The expression of the AIR protein shows as distinct dots in the nuclei of dendritic cells.

#### Detailed description of the invention

The present invention is based on studies aiming for the identification and characterization of the gene defect in APECED. In the  
10 sequence studies, a cosmid/BAC (bacterial artificial chromosome) contig of 520 kb covering four gene markers D21S1460-D21S1912-PFKL-D21S154 [Kudoh, J. *et al.*, DNA Res. 4 (1997) 45-52] was constructed, and genomic sequencing in this region was performed [Kawasaki, K. *et al.*, Genome Res. 7 (1997) 250-261]. From this genomic sequence information the distance between D21S1912 and PFKL was determined to be approximately 140 kb (Fig. 1).

Using a computer program, such as GRAIL and GENSCAN [Uberbacher, E. C. and Mural, R. J., Proc. Natl. Acad. Sci. USA 88 (1991) 11261-11265; Burge, C. and Karlin, S., J. Mol. Biol. 268 (1997) 78-94], gene  
20 screening in the partial sequencing data within this region was performed. GENSCAN predicted several genes between D21S1912 and PFKL. One of these genes located just proximal to the PFKL gene contained the previously trapped exon HC21EXc33 [Kudoh, J. *et al.*, DNA Res. 4 (1997) 45-52] or MDC04M06 [Chen, H. *et al.*, Genome Res. 6 (1996) 747-760]. A set of primers  
25 for polymerase chain reaction (PCR) was then designed from the predicted exons. The PCR screening of various cDNA libraries using these primers allowed the isolation of a cDNA clone containing the exon HC21EXc33 (exon 13) from the thymus cDNA library (Fig. 2A).

A 3'-rapid amplification of cDNA ends (3'-RACE) and 5'-RACE using  
30 Marathon<sup>TM</sup> cDNA Amplification Kit (Clontech Laboratories Inc, California, USA) according to manufacturer's protocol from the thymus cDNA library was performed using a primer c33F (sequence id. no. 7) and a primer 1R (sequence id. no. 8), respectively.

Sequencing analysis revealed a unique sequence of 2027 bp in  
35 overlapping PCR products that contains a 1635-bp open reading frame (ORF) from methionine at nt 128 to a TAG stop codon at nt 1763 encoding a predic-

ted novel protein designated AIR-1, for autoimmune regulator 1. AIR-1 encodes a protein of 545 amino acids with a predicted isoelectric point of 7.32 and a calculated molecular mass of 57,723 (Fig. 2B).

A 5'-RACE from the thymus cDNA using a primer 4R (sequence id. no. 9) resulted in an alternatively spliced product. Furthermore, two types of the cDNA clones were amplified with a primer pair 3F/c33R (sequence id. no. 10/sequence id. no. 11) and these clones encode for AIR-2 and AIR-3 proteins, sequence id. no. 4 and sequence id. no. 6, respectively (Fig. 2A) (sequence id. no. 3 and sequence id. no. 5). The AIR-2 and AIR-3 proteins consist of 348 and 254 amino acids, respectively (Fig. 2B). These results suggest that the APECED gene is transcribed as at least three types of mRNA by alternative splicing and/or use of an alternative 5' exon within the gene. RT-PCR analysis [Griffin, H. G. and Griffin, A. M., PCR Technology. Current Innovations, CRC Press, 1994] revealed that the AIR-1 transcript is also expressed in fetal liver (data not shown).

The APECED gene is approximately 13-kb in length and contains 15 exons, including the exon 1' specific to AIR-2 and AIR-3. It is transcribed in the direction of centromere to telomere (Figs 1, 2A). Based on this information, PCR primers were designed to amplify each exon from the genomic DNA and a mutation analysis of Swiss and Finnish APECED families was performed. Sequence comparison identified two mutations in the APECED gene of the patients (Fig. 3). The first mutation changes an Arg codon (CGA) to a stop codon (TGA) at amino acid position 257 in exon 6. This mutation was designated as R257stop mutation. The second mutation is a missense mutation that derived from the maternal chromosome in one Finnish patient (NP): a Lys codon (AAG) changes to a Glu codon (GAG) at amino acid position 42 in exon 2. This mutation is designated as K42E mutation (Figs 2A, 3C).

The R257stop mutation destroys a *TaqI* restriction enzyme site and the K42E mutation introduces a novel *TaqI* site. Thus these two mutations can be easily demonstrated in one or both alleles by *TaqI* digestion or by digestion using another enzyme cleaving at the recognition site 5'-TCGA-3'(Fig. 4).

The AIR-1 protein has strong homology in certain domains to the major autoantigens (Mi-2) associated with the autoimmune disease dermatomyositis [Seeig, H. P. *et al.*, Arthritis Rheum. 38 (1995) 1389-1399; Ge, Q. *et al.*, J. Clin. Invest. 96 (1995) 1730-1737], Sp140, a protein from the nuclear body, an organelle involved in the pathogenesis of certain types of

leukemia, and which is also the target of antibodies in the serum of patients with the autoimmune disease primary biliary cirrhosis [Bloch, D. B. *et al.*, J. Biol. Chem. 271 (1996) 29198-29204]. In addition, the homologies extend to other nuclear proteins such as TIF1 [Le Douarin, B. *et al.*, EMBO J. 14 (1995) 2020-2033], LYSP100 [Dent, A. L. *et al.*, Blood 88 (1996) 1423-1426], and putative yeast and *C. elegans* proteins. The AIR-1 protein homologies are principally in two PHD finger motifs (amino acid 299 to 340 and 434 to 475) (Fig. 5). AIR-1 also contains a proline-rich region (amino acid 350 to 430) (Fig. 2B). The PHD finger is a cysteine-rich structure that is distinguished from the RING finger (C3HC4) and LIM domain (C2HC5) because it contains a consensus of C4HC3. [Aasland, R. *et al.*, Trends Biochem. Sci. 20 (1995) 56-59]. The PHD finger motif is found in a number of chromatin-associated proteins such as HRX that is involved in the t(11:17) translocation in acute leukemia [Chaplin, T. *et al.*, Blood 86 (1995) 2073-2076]. The proline-rich region is assumed to be involved in protein-protein interaction or DNA binding. The presence of the PHD finger and proline-rich regions indicates a function for AIRs as transcription regulatory proteins. However, the AIR proteins have no apparent nuclear translocation signal, and thus other proteins containing such signal may interact with AIR to translocate it to the nucleus. In fact, the AIR proteins also have the LXXLL motif that is a signature sequence to bind to nuclear receptors [Heery, D. M. *et al.*, Nature 387 (1997) 733-736] (Fig. 2B).

The clinical picture of APECED and the observed immunological abnormality with strong autoimmune response towards several target organs and antigens suggest that the product of the APECED gene has a central role in immune (ontogeny) maturation and regulation of immune response towards self and nonself.

According to the diagnostic method of the invention, the presence of the defective APECED gene can be detected from a biological sample by any known detection method suitable for detecting mutations. Such methods include the method described by Saiki *et al.* [Proc. Natl. Acad. Sci USA 86 (1989) 6230-6234] utilizing hybridization to an allele specific oligonucleotide probe, or modifications thereof; the method described by Newton, C. R. *et al.* [Nucl. Acids Res. 17 (1989) 2503-2516] using the DNA sequences or DNA-fragments of the invention as probes; the solid phase minisequencing method described by Syvänen *et al.* [Genomics 8 (1990) 684-692] in which use is made of a biotinylated probe; or the oligonucleotide ligation method described

by Landegren, U. *et al.* [Science 241 (1988) 1077-1080]. Methods include the denaturing gradient gel electrophoresis (DGGE) [Fischer, S.G. and Lerman, L.S., PNAS 80 (1983) 1579-1583] or a modification of this method, constant denaturant gel electrophoresis (CDGE) [Hoving *et al.*, Genes Chromosomes Cancer 5 (1992) 97-103]. The mutation separation principle of DGGE and CDGE is based on the melting behavior of the DNA double helix of a given fragment.

Since the mutations of the APECED gene involve a site sensitive to *TaqI* digestion, the mutations are preferably detected in one or both alleles by *TaqI* digestion or by digestion using another enzyme cleaving at recognition site 5'-TCGA-3'. The chemical mismatch cleavage for mutation analysis can be used [Grompe, M. *et al.*, Proc. Natl. Acad. Sci. USA 86(15)(1989) 5888-5892].

In the diagnostic method of the invention the biological sample can be any tissue or body fluid containing cells, such as blood, e.g. umbilical cord blood, separated blood cells, such as lymphocytes, B-cells, T-cells etc., biopsy material, such as fetal liver or thymus biopsy, sperm, saliva, etc. The biological sample can be, where necessary, pretreated in a suitable manner known to those skilled in the art.

When the DNA sequence of the present invention is used therapeutically any techniques presently available for gene therapy can be employed. Accordingly, in the technique known as *ex vivo* therapy patient cells (e.g. umbilical cord blood from the fetus) with the defective gene are taken from the patient, DNA sequences encoding the normal (healthy) gene product incorporated in a carrier vector are transduced or transfected to the cells and the cells are returned to the patient. If the techniques known as *in situ* therapy is used, the DNA sequences encoding the normal gene product are first inserted to a suitable carrier vector, and the carrier is then introduced to the affected tissue, such as peripheral blood, liver or bone marrow. The carrier vector used can be a retrovirus vector, an adeno virus vector, an adeno associated virus (AAV) vector or an eucaryotic vector. The therapy can be performed intra utero or during adult life. Depending on the cells to be treated these techniques lead either to a transient cure, where cells from affected organ are treated, or to a permanent cure, in case of the treatment of stem cells.

The present invention provides means for an easy and more rapid diagnosis of the diseases related to immune maturation and regulation of

immune response towards self and nonself, such as APECED, and, specifically, enables prenatal diagnosis and carrier diagnosis. Furthermore, it provides a background for therapy.

The invention is now elucidated by the following non-limiting  
5 examples.

### Example 1

#### Localization of the APECED gene

Genomic sequencing of cosmid DNAs was performed by the shotgun method described by Kawasaki, K. *et al.*, Genome Res. 7 (1997) 250-  
10 261. Cosmids D1G8, D40G11, D9G11, D28B11, and D4G11 and gene marker D21S1912 are described by Kudoh, J. *et al.*, DNA Res. 4 (1997) 45-52].

#### cDNA cloning

The phage DNAs prepared from human thymus cDNA library (Clontech, HL1127a) were used as a PCR template. 20 ng of phage DNA  
15 which represents approximately  $4 \times 10^8$  phages was added to a 10 ml of reaction mixture containing 1x buffer [16mM  $(\text{NH}_4)_2\text{SO}_4$ , 50mM Tris-HCl, pH 9.2, 1.75 mM  $\text{MgCl}_2$ , 0.001% (w/v) gelatin), 0.2 mM each of dNTPs, 1M Betaine (Sigma), 0.35 U of Tap and Pwo DNA polymerase (EXpand Long Template PCR System, Boehringer Mannheim), and 0.5 mM of each of the  
20 primers, 2F and c33R, 2F and 4R, and 2F' and 2R', respectively.

The cDNA fragment was amplified by PCR using the following conditions: 94°C for 3 min., 35 cycles of 94°C for 30 sec, 60 °C for 30 sec in 2F/c33R and 2F/4R or 65°C for 30 sec in 2F'/2R', and 68°C for 90 sec. 3'- and 5'-RACE were carried out by Marathon cDNA Amplification Kit (Human  
25 Thymus; Clontech). PCR reaction was performed in a 10 µl volume containing 1x buffer (50 mM KCl, 10 mM Tris-HCl, pH 8.3, 1.5 mM  $\text{MgCl}_2$ , 0.001% (w/v) gelatin), 0.2 mM each of dNTPs, 0.25 U of AmpliTaq Gold polymerase (Perkin-Elmer), and 0.5 mM of each of the exon-specific primers. 3'-RACE product was amplified by PCR with the following conditions: 95°C for 9 min., 35 cycles  
30 of 94°C for 30 sec, 60°C for 30 sec, and 72°C for 30 sec.

The cDNA fragments were sequenced by the dye deoxy terminator cycle sequencing method (according to ABI PRISM Dye Terminator Cycle Sequencing Ready Reaction Kit protocol P/N 402078, Perkin Elmer Corporation, California) using specific primers, 2F and c33R, and AmpliTaq/FS

DNA polymerase (Perkin-Elmer), and then analyzed by using an automatic DNA sequencer (Applied Biosystems 377). Primer sequences used were

1R: 5'-GTTCCCGAGTGGAAGGCGCTGC-3' (sequence id. no. 8)

2F: 5'-GGATTCAGACCATGTCAGCTTCA-3' (sequence id. no. 12)

5 3F: 5'-GAGTTCAGGTACCCAGAGATGCTG-3' (sequence id. no. 10)

c33R: 5'-CTCGCTCAGAAGGGACTCCA-3' (sequence id. no. 11)

4R: 5'-AGGGGACAGGCAGGCCAGGT-3' (sequence id. no. 9)

2F': 5'-GTGCTGTTCAAGGACTACAAC-3' (sequence id. no. 13)

10 2R': 5'-TGGATGAGGATCCCCTCCACG-3' (sequence id. no. 14)

AP1: 5'-CCATCCTAATACGACTCACTATAGGGC-3' (sequence id. no. 15) and

c33F: 5'-GATGACACTGCCAGTCACGA-3' (sequence id. no. 7).

## Example 2

### 15 Mutation analysis of the APECED gene

For the mutation analysis the DNA samples were purified from peripheral blood mononuclear cells from patients with APECED and from suspected carriers of APECED and from normal healthy controls (according to Sambrook *et al.* 1989, Molecular Cloning. A Laboratory Manual. CSH Press)

20 and subjected to PCR using primers specific for all identified exons.

For sequencing the mutated exons, PCR fragments, 6F/6R in exon 6 and 49300F/49622R in exon 2, were amplified by PCR with the following conditions: 95°C for 9 min., 35 cycles of 94°C for 30 sec, 60°C for 30 sec and 72°C for 30 sec, and 94°C for 3 min., 35 cycles of 94°C for 30 sec, 60°C for 30 sec, and 68°C for 30 sec, respectively. The PCR products were sequenced using specific primers

6F: 5'-TGCAGGCTGTGGGAACTCCA-3' (sequence id. no. 16)

6R: 5'-AGAAAAAGAGCTGTACCCTGTG-3' (sequence id. no. 17)

3R: 5'-TGCAAGGAAGAGGGGCGTCAGC-3' (sequence id. no. 18)

30 49300F: 5'-TCCACCACAAGCCGAGGAGAT-3' (sequence id. no. 19) and 49622R: 5'-ACGGGCTCCTCAAACACCACT-3' (sequence id. no. 20).

In the mutation analysis by sequencing, two Swiss and three Finnish (HP1, HP2 and MP) patients with APECED were homozygous for R257stop allele, whereas one Finnish patient (NP) was heterozygous for this mutation (Fig. 3A, B). The R257stop mutation of NP was derived from the





lysis of 20 unaffected Japanese was performed and no mutations were found in any of these positions. These results demonstrate that the APECED gene is responsible for the pathogenesis of APECED.

Mutations were found in the AIR-1 transcript but not in the AIR-2  
5 and AIR-3 transcripts from all the APECED patients tested. Two Swiss and three Finnish (HP1, HP2 and MP) patients who are homozygous for the R257stop mutation completely lack functional AIR-1 protein but still have intact AIR-2 and AIR-3 proteins.

One common mutation seems responsible for the genetic defect in  
10 approximately 90% of the Finnish APECED cases and a haplotype analysis with the markers D21S141, D21S1912 and PFKL shows that the R257stop mutation is likely to be this common mutation [Björnses, P. *et al.*, Am. J. Hum. Genet. 59 (1996) 879-886].

#### Example 4

##### 15 Analysis of the AIR protein expression

In this example, synthetic peptides representing amino-acid sequences of the AIR-1 protein, were used to generate a polyvalent mouse antiserum against the AIR-1 protein.

For the peptide synthesis, two peptides were chosen according to  
20 the antigenicity prediction by Pepsort program (GCC package, Wisconsin, USA). The peptides AIR-1/2 and AIR-1/6 (TLHLKEKEGCPQAFH, sequence id. no. 25 and GKNKARSSSGPKPLV, sequence id. no. 26, respectively) representing exons 2 and 6, respectively, of the APECED gene were synthesized onto a branched lysine core (Fmoc8-Lys4-Lys2-Lys-betaAla-  
25 Wang resin, Calbiochem-Novabiochem, La Jolla, Ca, USA) resulting in an octameric multiple antigen peptide (MAP) [Tam, J. P. *et al.*, Proc. Natl. Acad. Sci. USA 85 (1988) 5409-5413; Adermann, K. *et al.*, in Solid Phase Synthesis, Biological and Biomedical Applications, pp. 429-432, Ed. R. Epton, Mayflower Worldwide Ltd., Birmingham, 1994], Syntheses were performed by Fmoc (N-  
30 (9-fluorenyl)methoxycarbonyl) chemistry on a simultaneous multiple peptide synthesizer (SMPS 350, Zinsser Analytic, Frankfurt, Germany). Purity of MAPs was analyzed by reverse-phase HPLC (System Gold, Beckman Instruments Inc, Fullerton, CA, USA).

To obtain murine polyclonal antibodies, eight-week old Balb/c mice  
35 were immunized with an intraperitoneal injection of 25 micrograms of each

peptide in 0,4 ml of a 1:1 mixture of Freund's Complete Adjuvant (Difco Laboratories, Detroit, MI, USA) and physiological saline (NaCl, 0,15 M). One month later the animals were boosted with an intramuscular injection of 35 micrograms of antigens in Freund's incomplete adjuvant and saline (1:1) (0,2 ml were distributed into four sites). Three weeks later the peptides in a dose of 50 micrograms/mouse were administered intravenously and sera were obtained 7 days later.

For the production of EBV transformed B-cells, peripheral blood leukocytes were obtained from healthy control persons. The B-cells were transformed with EBV (Epstein-Barr virus) using standard protocol, and the cell lines were maintained in RPMI 1640, supplemented with 10% FCS (fetal calf serum). An aliquot of cells were stimulated for 12 hours with 10 mg/ml of phytohemagglutinin (PHA) to obtain mitogen-activated T-cells.

Tissue samples were obtained from stillborn fetuses at six months gestational age. Fetal liver, spleen, thymus and lymphnodes were homogenized, the homogenates were cleared with centrifugations (20 000 rpm for 20 minutes) and the samples were used for western blot analysis.

For analysis of polyclonal sera, Elisa and western blot analysis were performed. Microtitre ELISA plates (Maxisorp, Nunc, Roskilde, Denmark) were coated with the peptides (1 micrograms /well in PBS, pH 7,5) at 4°C overnight and blocked with 2 % of BSA in PBS. The plates were then incubated with titrated mouse immune sera and normal (control) sera at room temperature for 4 h. Finally the bound peptide-specific antibodies were detected by use of anti-mouse HRP-labelled immunoglobulins (Dako A/S, Denmark) essentially as previously described [Ovod, V. A. *et al.*, AIDS 6 (1992) 25-34].

For western blotting, tissue homogenates, EBV transformed B-cells or PHA-activated T-cells were boiled for 10 minutes in 2x sample buffer (for tissue homogenates: 100 microliters of homogenate mixed with 100 microliters of sample buffer; for cells: one million cells/100 ml of buffer) and analyzed in western blotting as described in Ovod, V. A. *et al.*, *supra*.

The antisera so produced reacted with the AIR-1-protein low amount in normal fetal spleen, thymus and lymphonode as well as, in EBV-transformed B-cells and in PHA-activated T-cells. In the ELISA assay towards the immunogenic peptides, all four mice gave a strong reactivity towards the peptide used for the immunization. In the western blotting analysis using either

the tissue homogenates or stimulated T-cells or established B-cells, a strong band of approx. 60 kD molecular weight was seen in fetal liver (Fig. 6), while weaker bands of the same size were seen in the other samples.

### Example 5

#### 5 Identification of the expression of APECED in thymus and other lymphoid organs

mRNA *in situ* hybridization and immunohistochemistry were used to identify APECED-expressing cells in various normal fetal and adult human tissues. Thymus samples were obtained in conjunction of corrective surgery  
 10 from cardiac patients aged 2-19 years. Other tissue samples were obtained from surgical biopsy or from autopsy material. This was approved by Hospital Ethics Committees at Tampere University Hospital and Helsinki University Central Hospital. The tissue materials were stored frozen or formaldehyde fixed and paraffin embedded until used.

15 For mRNA *in situ* hybridization, three cDNA fragments for riboprobes were amplified by RT-PCR from thymus mRNA (Clontech) with primer pairs: 5'-ATG GCG ACG GAC GCG GCG CTA CGC-3' (seq. id. no. 27) and 5'-CCT GGA TGT ACT TCT TGG AGC CGC-3' (seq. id. no. 28), 5'-GAG CCC GAG GGG CCG TGG AGG GGA-3' (seq. id. no. 29) and 5'-GGC TGC  
 20 ACC TCC TGG ACT GTT GCC-3' (seq. id. no. 30), and 5'-GAT CCT GCT CAG GAG ACG TGA CCC-3' (seq. id. no. 31) and 5'-CAC CAG GCA AGG AGA GGC TCC CGG-3' (seq. id. no. 32), designed to amplify fragments spanning nucleotides 137 - 812, 738 - 1185 and 1554 - 2009 of the sequence id. no. 1, respectively. The amplified fragments were subcloned into a pCRII-  
 25 TOPO vector (Invitrogen).

For in vitro transcription the plasmids were linearized and sense and antisense probes were synthesized with digoxigenin-UTP as described (Boehringer Mannheim Nonradioactive *in situ* Hybridization Application Manual). Labeled probes were purified with MicroSpinG-50 columns  
 30 (Pharmacia Biotech). The pretreatment and hybridization of formaldehyde fixed, paraffin embedded tissue sections were performed as described by H. Breitschopf and G. Sucharek. (Boehringer Mannheim Nonradioactive *in situ* Hybridization Application Manual, Detection of mRNA on paraffin embedded material of the central nervous system with DIG-labeled RNA probes, pp 136-  
 35 138.)

For the preparation of antibodies to the AIR protein, the APECED cDNA (sequences 137 - 1774 of sequence id. no. 1) containing a full-coding region was amplified from Marathon human thymus cDNA (Clontech) with primers ExF and ExR2. The primer sequences for ExF and ExR2 were 5'-CCA CCC CAT GGC GAC GGA CG-3' (sequence id. no. 33) and 5'-GGA ATT CGG AGG GGA AGG GGG CCG CCG GA-3' (sequence id. no. 34). The amplified cDNA was digested with NcoI and EcoRI and cloned (pHPAIRE) into pET32a vector (Novagen). The protein was expressed in *E. coli* and purified by His-tag as described by manufacturer (QiaExpress Type IV Kit, Cat No 32149, Qiagen, USA).

To obtain murine polyclonal antibodies, Balb/c mice were immunised essentially as described in Example 4 using 100 micrograms of the bacterially expressed AIR protein with booster doses of 25 and 25 micrograms.

Japanese white rabbits were immunised with a synthetic peptide representing amino acids 526-545 (DGILQWAIQSMARPAAPFPS, sequence id. no. 36) of sequence id. no. 2. The specificities of the antisera were checked with ELISA and Western blotting using standard procedures.

For immunocytochemistry, frozen sections of tissue samples were fixed for 20 min in 4% paraformaldehyde. The AIR antibody (rabbit or mouse) in an appropriate dilution was incubated for 30 min at 37°C, with a biotin conjugated anti-mouse or anti-rabbit secondary antibody (Vector, CA, USA). The biotinylated antibody was revealed by incubating with Texas Red-avidin (Vector, CA, USA) for 30 min at 37°C.

With in situ hybridization, a positive signal was seen in a few cells in thymus medulla (Fig. 7A). The APECED *in situ* -positive cells were infrequent and scattered as single cells in the medulla, but occasionally one or two APECED-expressing cells were seen adjacent to or buried into the Hassal's corpuscles that represent conglomerates of medullary epithelial cells. In the positive cells, APECED mRNA was predominantly localized in the cell nucleus. In human adult lymph node tissues, infrequent cells expressed APECED mRNA in the medulla and occasionally in the paracortical region, too (Fig. 7B) No hybridization signal was seen in the germinal centers.

Immunohistochemistry with mouse and rabbit polyclonal antisera to the AIR protein showed strong reactivity with selected cells in thymus medulla, lymph nodes and fetal liver (Fig. 7C and 7D) The comparison of the reaction

pattern obtained by immunohistochemistry to that obtained by in situ hybridization clearly established that specific, rare cells in thymus medulla and lymph node medulla and paracortex express APECED mRNA and the AIR protein. By either method, neither mRNA nor protein was detected in other adult tissues studied, including the target organs for tissue destruction in APECED (adrenal glands, parathyroid glands, gonads). In human fetal tissues, APECED positive cells were seen, although extremely infrequently, in the stroma of placental chorionic villi and in the sinusoidal area of the liver. In the fetal liver, the APECED positive cells were often localized pairwise like mirror images, suggesting that the cells were undergoing mitosis. Rare APECED expressing cells were also found in fetal thymus but the expression was not observed in other fetal tissues.

At the subcellular level, the AIR protein localized in small nuclear dots in the adult thymus, giving a characteristic speckled pattern (Fig. 7C; and Fig. 8A and 8B), but localized in the cytoplasm of cells in lymph nodes. In the rare positive cells in fetal liver, many of which were mitotic, the AIR protein was localized in the cytoplasm.

#### Example 6

#### Characterization of the phenotype of the APECED positive cells in thymus

Double staining with two antibodies was used to further characterize the cell type expressing APECED gene. In view of the fact that dendritic cells (DC) and thymus epithelium are both involved in the regulation of immune maturation, expression of markers for these cells were studied.

For double immunofluorescence detection the AIR staining was performed as described in example 5 with rabbit anti-AIR serum. The slides were then incubated with a second primary antibody [AE1 (Neomarkers, CA, USA), AE3 (Neomarkers, CA, USA), CD11c (Immunotech, France), or CD83 (Immunotech, France)] in an appropriate dilution for 30 min at 37°C, and the reaction was revealed by incubating with a FITC conjugated secondary anti-mouse antibody (Vector, CA, USA) for 30 min at 37°C.

Antibodies reacting with low molecular weight basic (AE1) or high molecular weight acidic (AE3) cytokeratins stained the thymus in a reticular fashion, and the APECED positive cells were seen either buried into this net or in close apposition with the keratin-positive cells. Confocal microscopy

clearly demonstrated that some of the APECED positive cells were cytokeratin positive while some remained negative (Figure 8A). A co-localization was stronger with AE1 than with AE3. The distribution of epithelial (AE1 positive) and non-epithelial APECED expressing cells varied but in most thymus preparates more than half were epithelial.

Less than half of the APECED expressing cells in thymus stained with markers CD11c and CD83 that react with cells of the monocyte-macrophage-dendritic cell lineage. In most cases, the staining reaction was weak but a few cells showed an intensive staining with the given marker (Fig. 8B). CD83 costained 5 to 40 % of the APECED positive cells. Antibody CD11c, reported to be specific for mature dendritic cells, reacted with up to 5 - 10 % of the APECED positive cells. All APECED positive cells were strongly positive for HLA-DR staining, however (data not shown).

These results suggest that in thymus the APECED gene is in fact expressed in two distinct cell populations, one epithelial and the other non-epithelial. The latter cell type is likely the one also expressing the APECED gene in extrathymic lymphoid tissues.

#### Example 7

##### APECED expression in stimulated dendritic cells *in vitro*

To show an APECED expression in dendritic cells derived from peripheral blood monocytes that are DC precursors, these cells were cultured at the presence of cytokines using conditions that are known to lead to the expansion and maturation of dendritic cells.

Peripheral blood mononuclear cells were isolated by Ficoll-Hypaque centrifugation, and adherent cells were separated and cultured in the presence of human recombinant GM-CSF (1000 units/ml) and rhIL-4 (1000 units/ml, both from R&D Systems), as described [Schuler, G. and Romani, N., Adv. Exp. Med. Biol. 417 (1997) 7 - 13]. Cells were further cultured for three days with 1/4 V/V of macrophage conditioned media. Cells were harvested at two days intervals and samples were prepared for RT-PCR. For RT-PCR total RNA was purified from DCs by using a commercial kit from Clontech (USA) (Nucleospin RNA Kit) according to manufacturer's instructions. An aliquot of RNA was transferred into cDNA with a commercial kit from Pharmacia (Sweden) (First-strand Synthesis Kit) and PCR for this DNA sample was performed. For PCR the fragment was amplified with primers 5'- GAT CCT

GCT CAG GAG ACG TGA CCC-3' (seq. id. no. 31; 1554 -1577 of seq. id. no. 1 ) and 5'-GGA CTG AGG AAG GAG GTG TCC TTC -3' (seq. id. no. 35; 1818-1841 of seq. id. no. 1) with the following conditions: 35 cycles of 95°C for 1 min., 62°C for 30 sec and 72°C for 1 min. The 1x reaction mix contained  
5 50mM KCl, 10mM Tris-HCl, pH8.3, 1.5mM MgCl<sub>2</sub>, 0.001% (w/v) gelatin, 0.2mM each of dNTPs, 0.25 U of Dynazyme (Finnzymes, Finland). A fragment of 287bp was detected by 1.5% agarose electrophoresis.

Cytospin preparations were further made for immunohistochemistry.

During this 7 to 10 days culture period approximately half of the  
10 cells developed the characteristic veiled morphology of DC and their phenotypic cell markers (CD11c and CD83) corresponded to mature DCs (Figure 9). The APECED expression was studied by RT-PCR and immunocytochemistry at two to three days intervals. In the starting material, i.e. the adherent cell pool from peripheral blood, no APECED expression was  
15 found. After seven days of culture in the presence of GM-CSF and IL-4, RT-PCR showed APECED mRNA expression and immunofluorescence showed a few AIR specific nuclear dots. After an additional 3-day-culture with conditioned medium from macrophage cultures a strong speckled pattern of nuclear AIR expression was seen (Figure 9A). The RT-PCR analysis of the  
20 mature (10 days) culture confirmed the AIR protein expression.





## 22

AGG CTG CAC CGC ACG GAG ATC GCG GTG GCC GTG GAC AGC GCC TTC CCA 217  
 Arg Leu His Arg Thr Glu Ile Ala Val Ala Val Asp Ser Ala Phe Pro  
 15 20 25

CTG CTG CAC GCG CTG GCT GAC CAC GAC GTG GTC CCC GAG GAC AAG TTT 265  
 Leu Leu His Ala Leu Ala Asp His Asp Val Val Pro Glu Asp Lys Phe  
 30 35 40

CAG GAG ACG CTT CAT CTG AAG GAA AAG GAG GGC TGC CCC CAG GCC TTC 313  
 Gln Glu Thr Leu His Leu Lys Glu Lys Glu Gly Cys Pro Gln Ala Phe  
 45 50 55

CAC GCC CTC CTG TCC TGG CTG CTG ACC CAG GAC TCC ACA GCC ATC CTG 361  
 His Ala Leu Leu Ser Trp Leu Leu Thr Gln Asp Ser Thr Ala Ile Leu  
 60 65 70 75

GAC TTC TGG AGG GTG CTG TTC AAG GAC TAC AAC CTG GAG CGC TAT GGC 409  
 Asp Phe Trp Arg Val Leu Phe Lys Asp Tyr Asn Leu Glu Arg Tyr Gly  
 80 85 90

CGG CTG CAG CCC ATC CTG GAC AGC TTC CCC AAA GAT GTG GAC CTC AGC 457  
 Arg Leu Gln Pro Ile Leu Asp Ser Phe Pro Lys Asp Val Asp Leu Ser  
 95 100 105

CAG CCC CGG AAG GGG AGG AAG CCC CCG GCC GTC CCC AAG GCT TTG GTA 505  
 Gln Pro Arg Lys Gly Arg Lys Pro Pro Ala Val Pro Lys Ala Leu Val  
 110 115 120

CCG CCA CCC AGA CTC CCC ACC AAG AGG AAG GCC TCA GAA GAG GCT CGA 553  
 Pro Pro Pro Arg Leu Pro Thr Lys Arg Lys Ala Ser Glu Glu Ala Arg  
 125 130 135

GCT GCC GCG CCA GCA GCC CTG ACT CCA AGG GGC ACC GCC AGC CCA GGC 601  
 Ala Ala Ala Pro Ala Ala Leu Thr Pro Arg Gly Thr Ala Ser Pro Gly  
 140 145 150 155

TCT CAA CTG AAG GCC AAG CCC CCC AAG AAG CCG GAG AGC AGC GCA GAG 649  
 Ser Gln Leu Lys Ala Lys Pro Pro Lys Lys Pro Glu Ser Ser Ala Glu  
 160 165 170

CAG CAG CGC CTT CCA CTC GGG AAC GGG ATT CAG ACC ATG TCA GCT TCA 697  
 Gln Gln Arg Leu Pro Leu Gly Asn Gly Ile Gln Thr Met Ser Ala Ser  
 175 180 185

GTC CAG AGA GCT GTG GCC ATG TCC TCC GGG GAC GTC CCG GGA GCC CGA 745  
 Val Gln Arg Ala Val Ala Met Ser Ser Gly Asp Val Pro Gly Ala Arg  
 190 195 200

GGG GCC GTG GAG GGG ATC CTC ATC CAG CAG GTG TTT GAG TCA GGC GGC 793  
 Gly Ala Val Glu Gly Ile Leu Ile Gln Gln Val Phe Glu Ser Gly Gly  
 205 210 215

TCC AAG AAG TGC ATC CAG GTT GGC GGG GAG TTC TAC ACT CCC AGC AAG 841  
 Ser Lys Lys Cys Ile Gln Val Gly Gly Glu Phe Tyr Thr Pro Ser Lys  
 220 225 230 235

## 23

TTC GAA GAC TCC GGC AGT GGG AAG AAC AAG GCC CGC AGC AGC AGT GGC 889  
 Phe Glu Asp Ser Gly Ser Gly Lys Asn Lys Ala Arg Ser Ser Ser Gly  
 240 245 250

CCG AAG CCT CTG GTT CGA GCC AAG GGA GCC CAG GGC GCT GCC CCC GGT 937  
 Pro Lys Pro Leu Val Arg Ala Lys Gly Ala Gln Gly Ala Ala Pro Gly  
 255 260 265

GGA GGT GAG GCT AGG CTG GGC CAG CAG GGC AGC GTT CCC GCC CCT CTG 985  
 Gly Gly Glu Ala Arg Leu Gly Gln Gln Gly Ser Val Pro Ala Pro Leu  
 270 275 280

GCC CTC CCC AGT GAC CCC CAG CTC CAC CAG AAG AAT GAG GAC GAG TGT 1033  
 Ala Leu Pro Ser Asp Pro Gln Leu His Gln Lys Asn Glu Asp Glu Cys  
 285 290 295

GCC GTG TGT CGG GAC GGC GGG GAG CTC ATC TGC TGT GAC GGC TGC CCT 1081  
 Ala Val Cys Arg Asp Gly Gly Glu Leu Ile Cys Cys Asp Gly Cys Pro  
 300 305 310 315

CGG GCC TTC CAC CTG GCC TGC CTG TCC CCT CCG CTC CGG GAG ATC CCC 1129  
 Arg Ala Phe His Leu Ala Cys Leu Ser Pro Pro Leu Arg Glu Ile Pro  
 320 325 330

AGT GGG ACC TGG AGG TGC TCC AGC TGC CTG CAG GCA ACA GTC CAG GAG 1177  
 Ser Gly Thr Trp Arg Cys Ser Ser Cys Leu Gln Ala Thr Val Gln Glu  
 335 340 345

GTG CAG CCC CGG GCA GAG GAG CCC CGG CCC CAG GAG CCA CCC GTG GAG 1225  
 Val Gln Pro Arg Ala Glu Glu Pro Arg Pro Gln Glu Pro Pro Val Glu  
 350 355 360

ACC CCG CTC CCC CCG GGG CTT AGG TCG GCG GGA GAG GAG GTA AGA GGT 1273  
 Thr Pro Leu Pro Pro Gly Leu Arg Ser Ala Gly Glu Glu Val Arg Gly  
 365 370 375

CCA CCT GGG GAA CCC CTA GCC GGC ATG GAC ACG ACT CTT GTC TAC AAG 1321  
 Pro Pro Gly Glu Pro Leu Ala Gly Met Asp Thr Thr Leu Val Tyr Lys  
 380 385 390 395

CAC CTG CCG GCT CCG CCT TCT GCA GCC CCG CTG CCA GGG CTG GAC TCC 1369  
 His Leu Pro Ala Pro Pro Ser Ala Ala Pro Leu Pro Gly Leu Asp Ser  
 400 405 410

TCG GCC CTG CAC CCC CTA CTG TGT GTG GGT CCT GAG GGT CAG CAG AAC 1417  
 Ser Ala Leu His Pro Leu Leu Cys Val Gly Pro Glu Gly Gln Gln Asn  
 415 420 425

CTG GCT CCT GGT GCG CGT TGC GGG GTG TGC GGA GAT GGT ACG GAC GTG 1465  
 Leu Ala Pro Gly Ala Arg Cys Gly Val Cys Gly Asp Gly Thr Asp Val  
 430 435 440

## 24

CTG CGG TGT ACT CAC TGC GCC GCT GCC TTC CAC TGG CGC TGC CAC TTC 1513  
 Leu Arg Cys Thr His Cys Ala Ala Ala Phe His Trp Arg Cys His Phe  
 445 450 455

CCA GCC GGC ACC TCC CGG CCC GGG ACG GGC CTG CGC TGC AGA TCC TGC 1561  
 Pro Ala Gly Thr Ser Arg Pro Gly Thr Gly Leu Arg Cys Arg Ser Cys  
 460 465 470 475

TCA GGA GAC GTG ACC CCA GCC CCT GTG GAG GGG GTG CTG GCC CCC AGC 1609  
 Ser Gly Asp Val Thr Pro Ala Pro Val Glu Gly Val Leu Ala Pro Ser  
 480 485 490

CCC GCC CGC CTG GCC CCT GGG CCT GCC AAG GAT GAC ACT GCC AGT CAC 1657  
 Pro Ala Arg Leu Ala Pro Gly Pro Ala Lys Asp Asp Thr Ala Ser His  
 495 500 505

GAG CCC GCT CTG CAC AGG GAT GAC CTG GAG TCC CTT CTG AGC GAG CAC 1705  
 Glu Pro Ala Leu His Arg Asp Asp Leu Glu Ser Leu Leu Ser Glu His  
 510 515 520

ACC TTC GAT GGC ATC CTG CAG TGG GCC ATC CAG AGC ATG GCC CGT CCG 1753  
 Thr Phe Asp Gly Ile Leu Gln Trp Ala Ile Gln Ser Met Ala Arg Pro  
 525 530 535

GCG GCC CCC TTC CCC TCC TGA CCCAGATGG CCGGGACATG CAGCTCTGAT 1804  
 Ala Ala Pro Phe Pro Ser \*  
 540 545

GAGAGAGTGC TGAGAAGGAC ACCTCCTTCC TCAGTCCTGG AAGCCGGCCG GCTGGGATCA 1864

AGAAGGGGAC AGCGCCACCT CTTGTCACTG CTCGGCTGTA AACAGCTCTG TGTTCCTGGG 1924

GACACCAGCC ATCATGTGCC TGGAAATTAA ACCCTGCCCC ACTTCTCTAC TCTGGAAGTC 1984

CCCGGGAGCC TCTCCTTGCC TGGTGACCTA CTAAAAATAT AAAAATTAGC TG 2036

(2) INFORMATION FOR SEQ ID NO: 2:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 545 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2:

Met Ala Thr Asp Ala Ala Leu Arg Arg Leu Leu Arg Leu His Arg Thr  
 1 5 10 15

Glu Ile Ala Val Ala Val Asp Ser Ala Phe Pro Leu Leu His Ala Leu  
 20 25 30

Ala Asp His Asp Val Val Pro Glu Asp Lys Phe Gln Glu Thr Leu His  
 35 40 45

## 25

Leu Lys Glu Lys Glu Gly Cys Pro Gln Ala Phe His Ala Leu Leu Ser  
 50 55 60  
 Trp Leu Leu Thr Gln Asp Ser Thr Ala Ile Leu Asp Phe Trp Arg Val  
 65 70 75 80  
 Leu Phe Lys Asp Tyr Asn Leu Glu Arg Tyr Gly Arg Leu Gln Pro Ile  
 85 90 95  
 Leu Asp Ser Phe Pro Lys Asp Val Asp Leu Ser Gln Pro Arg Lys Gly  
 100 105 110  
 Arg Lys Pro Pro Ala Val Pro Lys Ala Leu Val Pro Pro Pro Arg Leu  
 115 120 125  
 Pro Thr Lys Arg Lys Ala Ser Glu Glu Ala Arg Ala Ala Ala Pro Ala  
 130 135 140  
 Ala Leu Thr Pro Arg Gly Thr Ala Ser Pro Gly Ser Gln Leu Lys Ala  
 145 150 155 160  
 Lys Pro Pro Lys Lys Pro Glu Ser Ser Ala Glu Gln Gln Arg Leu Pro  
 165 170 175  
 Leu Gly Asn Gly Ile Gln Thr Met Ser Ala Ser Val Gln Arg Ala Val  
 180 185 190  
 Ala Met Ser Ser Gly Asp Val Pro Gly Ala Arg Gly Ala Val Glu Gly  
 195 200 205  
 Ile Leu Ile Gln Gln Val Phe Glu Ser Gly Gly Ser Lys Lys Cys Ile  
 210 215 220  
 Gln Val Gly Gly Glu Phe Tyr Thr Pro Ser Lys Phe Glu Asp Ser Gly  
 225 230 235 240  
 Ser Gly Lys Asn Lys Ala Arg Ser Ser Ser Gly Pro Lys Pro Leu Val  
 245 250 255  
 Arg Ala Lys Gly Ala Gln Gly Ala Ala Pro Gly Gly Gly Glu Ala Arg  
 260 265 270  
 Leu Gly Gln Gln Gly Ser Val Pro Ala Pro Leu Ala Leu Pro Ser Asp  
 275 280 285  
 Pro Gln Leu His Gln Lys Asn Glu Asp Glu Cys Ala Val Cys Arg Asp  
 290 295 300  
 Gly Gly Glu Leu Ile Cys Cys Asp Gly Cys Pro Arg Ala Phe His Leu  
 305 310 315 320  
 Ala Cys Leu Ser Pro Pro Leu Arg Glu Ile Pro Ser Gly Thr Trp Arg  
 325 330 335

09506636 110300

Cys Ser Ser Cys Leu Gln Ala Thr Val Gln Glu Val Gln Pro Arg Ala  
 340 345 350  
 Glu Glu Pro Arg Pro Gln Glu Pro Pro Val Glu Thr Pro Leu Pro Pro  
 355 360 365  
 Gly Leu Arg Ser Ala Gly Glu Glu Val Arg Gly Pro Pro Gly Glu Pro  
 370 375 380  
 Leu Ala Gly Met Asp Thr Thr Leu Val Tyr Lys His Leu Pro Ala Pro  
 385 390 395 400  
 Pro Ser Ala Ala Pro Leu Pro Gly Leu Asp Ser Ser Ala Leu His Pro  
 405 410 415  
 Leu Leu Cys Val Gly Pro Glu Gly Gln Gln Asn Leu Ala Pro Gly Ala  
 420 425 430  
 Arg Cys Gly Val Cys Gly Asp Gly Thr Asp Val Leu Arg Cys Thr His  
 435 440 445  
 Cys Ala Ala Ala Phe His Trp Arg Cys His Phe Pro Ala Gly Thr Ser  
 450 455 460  
 Arg Pro Gly Thr Gly Leu Arg Cys Arg Ser Cys Ser Gly Asp Val Thr  
 465 470 475 480  
 Pro Ala Pro Val Glu Gly Val Leu Ala Pro Ser Pro Ala Arg Leu Ala  
 485 490 495  
 Pro Gly Pro Ala Lys Asp Asp Thr Ala Ser His Glu Pro Ala Leu His  
 500 505 510  
 Arg Asp Asp Leu Glu Ser Leu Leu Ser Glu His Thr Phe Asp Gly Ile  
 515 520 525  
 Leu Gln Trp Ala Ile Gln Ser Met Ala Arg Pro Ala Ala Pro Phe Pro  
 530 535 540  
 Ser \*  
 545

(2) INFORMATION FOR SEQ ID NO: 3:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 1545 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

0950653 10300

## (ix) FEATURE:

(A) NAME/KEY: CDS  
 (B) LOCATION:237..1283  
 (D) OTHER INFORMATION:/product= "AIR-2"

## (ix) FEATURE:

(A) NAME/KEY: mat\_peptide  
 (B) LOCATION:237..1280  
 (D) OTHER INFORMATION:/product= "AIR-2"

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3:

```

AGAGAAAGTG AGGTCTTCTC AGGCTCTTAA GAGCATGGCG TTTGGTCCAG GCTGTACCCG      60
CTGCTCTCAG CTGGGCCCGT GGGTGGGCCG GGC GCCCCTG CTATAGCCAG GAGGTCAAGG      120
ATCCACTGGG AATGCCATGC TCATCTTTCG TCCCAGCAT GGTTCCTTAA TGGGGTAGAA      180
GCAGGTCGGG AGAGACCTCC CTGGGCCTGG CCCCCTGCC CTGTGAGGAA GGGTTC          236
ATG TGG TTG GTG TAC AGT TCC GGG GCC CCT GGA ACG CAG CAG CCT GCA          284
Met Trp Leu Val Tyr Ser Ser Gly Ala Pro Gly Thr Gln Gln Pro Ala
  1             5             10             15

AGA AAC CGG GTT TTC TTC CCA ATA GGG ATG GCC CCG GGG GGT GTC TGT          332
Arg Asn Arg Val Phe Phe Pro Ile Gly Met Ala Pro Gly Gly Val Cys
      20             25             30

TGG AGA CCA GAT GGA TGG GGA ACA GGT GGT CAG GGC AGA ATT TCA GGC          380
Trp Arg Pro Asp Gly Trp Gly Thr Gly Gly Gln Gly Arg Ile Ser Gly
      35             40             45

CCT GGC AGC ATG GGA GCA GGG CAG AGA CTG GGG AGT TCA GGT ACC CAG          428
Pro Gly Ser Met Gly Ala Gly Gln Arg Leu Gly Ser Ser Gly Thr Gln
      50             55             60

AGA TGC TGC TGG GGG AGC TGT TTT GGG AAG GAG GTG GCT CTC AGG AGG          476
Arg Cys Cys Trp Gly Ser Cys Phe Gly Lys Glu Val Ala Leu Arg Arg
      65             70             75             80

GTG CTG CAC CCC AGC CCA GTC TGC ATG GGC GTC TCT TGC CTG TGC CAG          524
Val Leu His Pro Ser Pro Val Cys Met Gly Val Ser Cys Leu Cys Gln
      85             90             95

AAG AAT GAG GAC GAG TGT GCC GTG TGT CGG GAC GGC GGG GAG CTC ATC          572
Lys Asn Glu Asp Glu Cys Ala Val Cys Arg Asp Gly Gly Glu Leu Ile
      100            105            110

TGC TGT GAC GGC TGC CCT CGG GCC TTC CAC CTG GCC TGC CTG TCC CCT          620
Cys Cys Asp Gly Cys Pro Arg Ala Phe His Leu Ala Cys Leu Ser Pro
      115            120            125

```

## 28

CCG CTC CGG GAG ATC CCC AGT GGG ACC TGG AGG TGC TCC AGC TGC CTG 668  
 Pro Leu Arg Glu Ile Pro Ser Gly Thr Trp Arg Cys Ser Ser Cys Leu  
 130 135 140

CAG GCA ACA GTC CAG GAG GTG CAG CCC CGG GCA GAG GAG CCC CGG CCC 716  
 Gln Ala Thr Val Gln Glu Val Gln Pro Arg Ala Glu Glu Pro Arg Pro  
 145 150 155 160

CAG GAG CCA CCC GTG GAG ACC CCG CTC CCC CCG GGG CTT AGG TCG GCG 764  
 Gln Glu Pro Pro Val Glu Thr Pro Leu Pro Pro Gly Leu Arg Ser Ala  
 165 170 175

GGA GAG GAG GTA AGA GGT CCA CCT GGG GAA CCC CTA GCC GGC ATG GAC 812  
 Gly Glu Glu Val Arg Gly Pro Pro Gly Glu Pro Leu Ala Gly Met Asp  
 180 185 190

ACG ACT CTT GTC TAC AAG CAC CTG CCG GCT CCG CCT TCT GCA GCC CCG 860  
 Thr Thr Leu Val Tyr Lys His Leu Pro Ala Pro Pro Ser Ala Ala Pro  
 195 200 205

CTG CCA GGG CTG GAC TCC TCG GCC CTG CAC CCC CTA CTG TGT GTG GGT 908  
 Leu Pro Gly Leu Asp Ser Ser Ala Leu His Pro Leu Leu Cys Val Gly  
 210 215 220

CCT GAG GGT CAG CAG AAC CTG GCT CCT GGT GCG CGT TGC GGG GTG TGC 956  
 Pro Glu Gly Gln Gln Asn Leu Ala Pro Gly Ala Arg Cys Gly Val Cys  
 225 230 235 240

GGA GAT GGT ACG GAC GTG CTG CGG TGT ACT CAC TGC GCC GCT GCC TTC 1004  
 Gly Asp Gly Thr Asp Val Leu Arg Cys Thr His Cys Ala Ala Ala Phe  
 245 250 255

CAC TGG CGC TGC CAC TTC CCA GCC GGC ACC TCC CGG CCC GGG ACG GGC 1052  
 His Trp Arg Cys His Phe Pro Ala Gly Thr Ser Arg Pro Gly Thr Gly  
 260 265 270

CTG CGC TGC AGA TCC TGC TCA GGA GAC GTG ACC CCA GCC CCT GTG GAG 1100  
 Leu Arg Cys Arg Ser Cys Ser Gly Asp Val Thr Pro Ala Pro Val Glu  
 275 280 285

GGG GTG CTG GCC CCC AGC CCC GCC CGC CTG GCC CCT GGG CCT GCC AAG 1148  
 Gly Val Leu Ala Pro Ser Pro Ala Arg Leu Ala Pro Gly Pro Ala Lys  
 290 295 300

GAT GAC ACT GCC AGT CAC GAG CCC GCT CTG CAC AGG GAT GAC CTG GAG 1196  
 Asp Asp Thr Ala Ser His Glu Pro Ala Leu His Arg Asp Asp Leu Glu  
 305 310 315 320

TCC CTT CTG AGC GAG CAC ACC TTC GAT GGC ATC CTG CAG TGG GCC ATC 1244  
 Ser Leu Leu Ser Glu His Thr Phe Asp Gly Ile Leu Gln Trp Ala Ile  
 325 330 335

CAG AGC ATG GCC CGT CCG GCG GCC CCC TTC CCC TCC TGA CCCCAGATGG 1293  
 Gln Ser Met Ala Arg Pro Ala Ala Pro Phe Pro Ser \*  
 340 345

CCGGGACATG CAGCTCTGAT GAGAGAGTGC TGAGAAGGAC ACCTCCTTCC TCAGTCCTGG 1353

AAGCCGGCCG GCTGGGATCA AGAAGGGGAC AGCGCCACCT CTTGTCACTG CTCGGCTGTA 1413

AACAGCTCTG TGTTCCTGGG GACACCAGCC ATCATGTGCC TGGAAATTAA ACCCTGCCCC 1473

ACTTCTCTAC TCTGGAAGTC CCCGGGAGCC TCTCCTTGCC TGGTGACCTA CTAAAAATAT 1533

AAAAATTAGC TG 1545

## (2) INFORMATION FOR SEQ ID NO: 4:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 348 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: protein

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4:

Met	Trp	Leu	Val	Tyr	Ser	Ser	Gly	Ala	Pro	Gly	Thr	Gln	Gln	Pro	Ala	1	5	10	15
Arg	Asn	Arg	Val	Phe	Phe	Pro	Ile	Gly	Met	Ala	Pro	Gly	Gly	Val	Cys	20	25	30	
Trp	Arg	Pro	Asp	Gly	Trp	Gly	Thr	Gly	Gly	Gln	Gly	Arg	Ile	Ser	Gly	35	40	45	
Pro	Gly	Ser	Met	Gly	Ala	Gly	Gln	Arg	Leu	Gly	Ser	Ser	Gly	Thr	Gln	50	55	60	
Arg	Cys	Cys	Trp	Gly	Ser	Cys	Phe	Gly	Lys	Glu	Val	Ala	Leu	Arg	Arg	65	70	75	80
Val	Leu	His	Pro	Ser	Pro	Val	Cys	Met	Gly	Val	Ser	Cys	Leu	Cys	Gln	85	90	95	
Lys	Asn	Glu	Asp	Glu	Cys	Ala	Val	Cys	Arg	Asp	Gly	Gly	Glu	Leu	Ile	100	105	110	
Cys	Cys	Asp	Gly	Cys	Pro	Arg	Ala	Phe	His	Leu	Ala	Cys	Leu	Ser	Pro	115	120	125	
Pro	Leu	Arg	Glu	Ile	Pro	Ser	Gly	Thr	Trp	Arg	Cys	Ser	Ser	Cys	Leu	130	135	140	
Gln	Ala	Thr	Val	Gln	Glu	Val	Gln	Pro	Arg	Ala	Glu	Glu	Pro	Arg	Pro	145	150	155	160



[illegible][illegible][illegible]

- [illegible]

[illegible]

- [illegible]

[illegible]

- [illegible]

AGAGAAAGTG	AGGTCTTCTC	AGGCTCTTAA	GAGCATGGCG	TTTGGTCCAG	GCTGTACCCG		60
CTGCTCTCAG	CTGGGCCCCGT	GGGTGGGCCG	GGCGCCCCCTG	CTATAGCCAG	GAGGTCAAGG		120
ATCCACTGGG	AATGCCATGC	TCATCTTTCG	TCCCCAGCAT	GGTTTCTTAA	TGGGGTAGAA		180
GCAGGTCGGG	AGAGACCTCC	CTGGGCCTGG	CCCCACTGCC	CTGTGAGGAA	GGGTTC		236
ATG TGG TTG GTG TAC AGT TCC GGG GCC CCT GGA ACG CAG CAG CCT GCA							284
Met Trp Leu Val Tyr Ser Ser Gly Ala Pro Gly Thr Gln Gln Pro Ala							
1	5		10		15		
AGA AAC CGG GTT TTC TTC CCA ATA GGG ATG GCC CCG GGG GGT GTC TGT							332
Arg Asn Arg Val Phe Phe Pro Ile Gly Met Ala Pro Gly Gly Val Cys							
	20		25		30		
TGG AGA CCA GAT GGA TGG GGA ACA GGT GGT CAG GGC AGA ATT TCA GGC							380
Trp Arg Pro Asp Gly Trp Gly Thr Gly Gly Gln Gly Arg Ile Ser Gly							
	35		40		45		
CCT GGC AGC ATG GGA GCA GGG CAG AGA CTG GGG AGT TCA GGT ACC CAG							428
Pro Gly Ser Met Gly Ala Gly Gln Arg Leu Gly Ser Ser Gly Thr Gln							
	50		55		60		
AGA TGC TGC TGG GGG AGC TGT TTT GGG AAG GAG GTG GCT CTC AGG AGG							476
Arg Cys Cys Trp Gly Ser Cys Phe Gly Lys Glu Val Ala Leu Arg Arg							
65		70		75		80	
GTG CTG CAC CCC AGC CCA GTC TGC ATG GGC GTC TCT TGC CTG TGC CAG							524
Val Leu His Pro Ser Pro Val Cys Met Gly Val Ser Cys Leu Cys Gln							
	85		90		95		
AAG AAT GAG GAC GAG TGT GCC GTG TGT CGG GAC GGC GGG GAG CTC ATC							572
Lys Asn Glu Asp Glu Cys Ala Val Cys Arg Asp Gly Gly Glu Leu Ile							
	100		105		110		
TGC TGT GAC GGC TGC CCT CGG GCC TTC CAC CTG GCC TGC CTG TCC CCT							620
Cys Cys Asp Gly Cys Pro Arg Ala Phe His Leu Ala Cys Leu Ser Pro							
	115		120		125		
CCG CTC CGG GAG ATC CCC AGT GGG ACC TGG AGG TGC TCC AGC TGC CTG							668
Pro Leu Arg Glu Ile Pro Ser Gly Thr Trp Arg Cys Ser Ser Cys Leu							
	130		135		140		
CAG GCA ACA GTC CAG GAG GTG CAG CCC CGG GCA GAG GAG CCC CGG CCC							716
Gln Ala Thr Val Gln Glu Val Gln Pro Arg Ala Glu Glu Pro Arg Pro							
145		150		155		160	
CAG GAG CCA CCC GTG GAG ACC CCG CTC CCC CCG GGG CTT AGG TCG GCG							764
Gln Glu Pro Pro Val Glu Thr Pro Leu Pro Pro Gly Leu Arg Ser Ala							
	165		170		175		

## 32

GGA GAG GAG CCC CGC TGC CAG GGC TGG ACT CCT CGG CCC TGC ACC CCC 812  
 Gly Glu Glu Pro Arg Cys Gln Gly Trp Thr Pro Arg Pro Cys Thr Pro  
 180 185 190

TAC TGT GTG TGG GTC CTG AGG GTC AGC AGA ACC TGG CTC CTG GTG CGC 860  
 Tyr Cys Val Trp Val Leu Arg Val Ser Arg Thr Trp Leu Leu Val Arg  
 195 200 205

GTT GCG GGG TGT GCG GAG ATG GTA CGG ACG TGC TGC GGT GTA CTC ACT 908  
 Val Ala Gly Cys Ala Glu Met Val Arg Thr Cys Cys Gly Val Leu Thr  
 210 215 220

GCG CCG CTG CCT TCC ACT GGC GCT GCC ACT TCC CAG CCG GCA CCT CCC 956  
 Ala Pro Leu Pro Ser Thr Gly Ala Ala Thr Ser Gln Pro Ala Pro Pro  
 225 230 235 240

GGC CCG GGA CGG GCC TGC GCT GCA GAT CCT GCT CAG GAG ACG TGA 1001  
 Gly Pro Gly Arg Ala Cys Ala Ala Asp Pro Ala Gln Glu Thr \*  
 245 250 255

CCCCAGCCCC TGTGGAGGGG GTGCTGGCCC CCAGCCCCGC CCGCCTGGCC CCTGGGCCTG 1061

CCAAGGATGA CACTGCCAST CACGAGCCCG CTCTGCACAG GGATGACCTG GAGTCCCTTC 1121

TGAGCGAGCA CACCTTCGAT GGCATCCTGC AGTGGGCCAT CCAGAGCATG GCCCGTCCGG 1181

CGGCCCCCTT CCCCTCCTGA CCCCAGATGG CCGGGACATG CAGCTCTGAT GAGAGAGTGC 1241

TGAGAAGGAC ACCTCCTTCC TCAGTCCTGG AAGCCGGCCG GCTGGGATCA AGAAGGGGAC 1301

AGCGCCACCT CTTGTCAGTG CTCGGCTGTA AACAGCTCTG TGTTCCTGGG GACACCAGCC 1361

ATCATGTGCC TGGAAATTAA ACCCTGCCCC ACTTCTCTAC TCTGGAAGTC CCCGGGAGCC 1421

TCTCCTTGCC TGGTGACCTA CTAAAAATAT AAAAATTAGC TG 1463

## (2) INFORMATION FOR SEQ ID NO: 6:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 254 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: protein

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 6:

Met Trp Leu Val Tyr Ser Ser Gly Ala Pro Gly Thr Gln Gln Pro Ala  
 1 5 10 15

Arg Asn Arg Val Phe Phe Pro Ile Gly Met Ala Pro Gly Gly Val Cys  
 20 25 30

Trp Arg Pro Asp Gly Trp Gly Thr Gly Gly Gln Gly Arg Ile Ser Gly  
 35 40 45

33

Pro Gly Ser Met Gly Ala Gly Gln Arg Leu Gly Ser Ser Gly Thr Gln  
50 55 60

Arg Cys Cys Trp Gly Ser Cys Phe Gly Lys Glu Val Ala Leu Arg Arg  
65 70 75 80

Val Leu His Pro Ser Pro Val Cys Met Gly Val Ser Cys Leu Cys Gln  
85 90 95

Lys Asn Glu Asp Glu Cys Ala Val Cys Arg Asp Gly Gly Glu Leu Ile  
100 105 110

Cys Cys Asp Gly Cys Pro Arg Ala Phe His Leu Ala Cys Leu Ser Pro  
115 120 125

Pro Leu Arg Glu Ile Pro Ser Gly Thr Trp Arg Cys Ser Ser Cys Leu  
130 135 140

Gln Ala Thr Val Gln Glu Val Gln Pro Arg Ala Glu Glu Pro Arg Pro  
145 150 155 160

Gln Glu Pro Pro Val Glu Thr Pro Leu Pro Pro Gly Leu Arg Ser Ala  
165 170 175

Gly Glu Glu Pro Arg Cys Gln Gly Trp Thr Pro Arg Pro Cys Thr Pro  
180 185 190

Tyr Cys Val Trp Val Leu Arg Val Ser Arg Thr Trp Leu Leu Val Arg  
195 200 205

Val Ala Gly Cys Ala Glu Met Val Arg Thr Cys Cys Gly Val Leu Thr  
210 215 220

Ala Pro Leu Pro Ser Thr Gly Ala Ala Thr Ser Gln Pro Ala Pro Pro  
225 230 235 240

Gly Pro Gly Arg Ala Cys Ala Ala Asp Pro Ala Gln Glu Thr \*

245 250 255

## (2) INFORMATION FOR SEQ ID NO: 7:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 20 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 7:

GATGACACTG CCAATCACGA

20

00506633 103000

(2) INFORMATION FOR SEQ ID NO: 8:

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 22 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 8:

GTTCCCGAGT GGAAGGCGCT GC

22

(2) INFORMATION FOR SEQ ID NO: 9:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 20 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 9:

AGGGGACAGG CAGGCCAGGT

20

(2) INFORMATION FOR SEQ ID NO: 10:

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 24 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 10:

GAGTTCAGGT ACCCAGAGAT GCTG

24

(2) INFORMATION FOR SEQ ID NO: 11:

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 20 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 11:

CTCGCTCAGA AGGGACTCCA

20

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 23 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

GGATTCAGAC CATGTCAGCT TCA

23

(i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 21 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

GTGCTGTTCA AGGACTACAA C

21

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

TGGATGAGGA TCCCCTCCAC G

21

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 27 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

CCATCCTAAT ACGACTCACT ATAGGGC

27

20

22

22

21

## (2) INFORMATION FOR SEQ ID NO: 20:

- (i) SEQUENCE CHARACTERISTICS:  
    (A) LENGTH: 21 base pairs  
    (B) TYPE: nucleic acid  
    (C) STRANDEDNESS: single  
    (D) TOPOLOGY: linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 20:

ACGGGCTCCT CAAACACCAC T

21

## (2) INFORMATION FOR SEQ ID NO: 21:

- (i) SEQUENCE CHARACTERISTICS:  
    (A) LENGTH: 24 base pairs  
    (B) TYPE: nucleic acid  
    (C) STRANDEDNESS: single  
    (D) TOPOLOGY: linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 21:

TGGAGATGGG CAGGCCGCGAG GGTG

24

## (2) INFORMATION FOR SEQ ID NO: 22:

- (i) SEQUENCE CHARACTERISTICS:  
    (A) LENGTH: 24 base pairs  
    (B) TYPE: nucleic acid  
    (C) STRANDEDNESS: single  
    (D) TOPOLOGY: linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 22:

CAGTCCAGCT GGGCTGAGCA GGTG

24

## (2) INFORMATION FOR SEQ ID NO: 23:

- (i) SEQUENCE CHARACTERISTICS:  
    (A) LENGTH: 24 base pairs  
    (B) TYPE: nucleic acid  
    (C) STRANDEDNESS: single  
    (D) TOPOLOGY: linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 23:

GCGGCTCCAA GAAGTGCATC CAGG

24



## (2) INFORMATION FOR SEQ ID NO: 24:

- (i) SEQUENCE CHARACTERISTICS:  
    (A) LENGTH: 24 base pairs  
    (B) TYPE: nucleic acid  
    (C) STRANDEDNESS: single  
    (D) TOPOLOGY: linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 24:

CTCCACCCTG CAAGGAAGAG GGGC

24

## (2) INFORMATION FOR SEQ ID NO: 25:

- (i) SEQUENCE CHARACTERISTICS:  
    (A) LENGTH: 15 amino acids  
    (B) TYPE: amino acid  
    (C) STRANDEDNESS:  
    (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: peptide

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 25:

Thr	Leu	His	Leu	Lys	Glu	Lys	Glu	Gly	Cys	Pro	Gln	Ala	Phe	His
1				5				10					15	

## (2) INFORMATION FOR SEQ ID NO: 26:

- (i) SEQUENCE CHARACTERISTICS:  
    (A) LENGTH: 15 amino acids  
    (B) TYPE: amino acid  
    (C) STRANDEDNESS:  
    (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: peptide

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 26:

Gly	Lys	Asn	Lys	Ala	Arg	Ser	Ser	Ser	Gly	Pro	Lys	Pro	Leu	Val
1				5				10					15	

## (2) INFORMATION FOR SEQ ID NO: 27:

- (i) SEQUENCE CHARACTERISTICS:  
    (A) LENGTH: 24 base pairs  
    (B) TYPE: nucleic acid  
    (C) STRANDEDNESS: single  
    (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 27:

ATGGCGACGG ACGCGGCGCT ACGC

(2) INFORMATION FOR SEQ ID NO: 28:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 24 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 28:

CCTGGATGTA CTTCTTGGAG CCGC

(2) INFORMATION FOR SEQ ID NO: 29:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 24 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 29:

GAGCCCGAGG GGCCGTGGAG GGGA

(2) INFORMATION FOR SEQ ID NO: 30:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 24 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 30:

GGCTGCACCT CCTGGACTGT TGCC

(2) INFORMATION FOR SEQ ID NO: 31:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 24 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 31:

GATCCTGCTC AGGAGACGTG ACCC

(2) INFORMATION FOR SEQ ID NO: 32:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 24 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 32:

CACCAGGCAA GGAGAGGCTC CCGG

(2) INFORMATION FOR SEQ ID NO: 33:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 20 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 33:

CCACCCCATG GCGACGGACG

(2) INFORMATION FOR SEQ ID NO: 34:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 29 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 34:

GGAATTCGGA GGGGAAGGGG GCCGCCGGA

(2) INFORMATION FOR SEQ ID NO: 35:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 24 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 35:

GGACTGAGGA AGGAGGTGTC CTTC

2) INFORMATION FOR SEQ ID NO: 36:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS:
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 36:

Asp	Gly	Ile	Leu	Gln	Trp	Ala	Ile	Gln	Ser	Met	Ala	Arg	Pro	Ala	Ala	Pro	Phe	Pro	Ser
1				5					10					15				20	

## Claims

1. An isolated DNA sequence characterized by comprising the sequence id. no. 1 or a functional fragment or variant thereof encoding a protein having the same functional activity, or an functionally equivalent isolated DNA sequence hybridizable thereto.

2. An isolated DNA sequence according to claim 1, characterized in that it is associated with diseases related to immune maturation and regulation of immune response towards self and nonself, such as autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED).

3. An isolated DNA-sequence according to claim 1 or 2, characterized in that it includes a gene defect responsible for APECED.

4. A DNA sequence according to claim 1, characterized by having the sequence according to sequence id. no 1 or a functional fragment thereof having the sequence according to sequence id. no 3 or sequence id. no 5.

5. A protein characterized by comprising the amino acid sequence id. no. 2 or a functional fragment or variant thereof having the same functional properties.

6. A protein according to claim 5, characterized in that it is associated diseases related to immune maturation and regulation of immune response towards self and nonself, such as autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED).

7. A protein according to claim 5 or 6, characterized by having the amino acid sequence id. no. 2, or a functional fragment thereof having the sequence according to sequence id. no. 4, or a functional fragment thereof having the sequence according to sequence id. no 6.

8. A protein according to any of claims 5 to 7, characterized by having distinct structural motifs, including the PHD finger motif (PHD), the LXXLL motif (L), proline-rich region (PRR), and cystein-rich region (CRR).

9. A method for the diagnosis of diseases related to immune maturation and regulation of immune response towards self and nonself, characterized by detecting in a biological specimen the presence of a DNA sequence comprising the sequence id. no. 1 or a functional fragment or variant thereof encoding a protein having the same functional activity, or a functionally equivalent isolated DNA-sequence hybridizable thereto.

10. A method according to claim 9, characterized in that the DNA sequence is associated with APECED.

5 11. A method according to claim 9 or 10, characterized in that the DNA sequence includes a gene defect responsible for APECED.

12. A method according to claim 11, characterized in that the gene defect to be detected includes a "C" to "T" transition resulting in the "Arg" to "Stop" nonsense mutation at amino acid position 257 and/or a "A" to "G" transversion resulting in the "Lys" to "Glu" missense mutation at amino  
10 acid position 42.

13. A method according to any one of claims 9 to 12, characterized in that DNA techniques are used for the detection.

14. A method according to any one of claims 9 to 13, characterized in that the detection takes advantage of TaqI or another  
15 enzyme cleaving at recognition site 5'-TCGA-3' digestion.

15. A method according to any one of claims 9 to 14, characterized in that the disease is autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED).

16. A method for the diagnosis of diseases related to immune  
20 maturation and regulation of immune response towards self and nonself, characterized by detecting in a biological specimen the presence or the absence of a protein comprising the sequence id. no. 2, or a functional fragment thereof having the sequence according to sequence id. no. 4, or a functional fragment thereof having the sequence according to sequence id.  
25 no. 6.

17. A method according to claim 16, characterized in that the protein is associated with APECED.

18. A method according to claim 16 or 17, characterized in that the disease is autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED).  
30

19. The use of the DNA sequence according to any one of claims 1 to 4 in the diagnosis of diseases related to immune maturation and regulation of immune response towards self and nonself, such as autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy  
35 (APECED).

20. The use of the protein according to any one of claims 5 to 7 in the diagnosis of diseases related to immune maturation and regulation of immune response towards self and nonself, such as autoimmune poly-  
5 endocrinopathy-candidiasis-ectodermal dystrophy (APECED).


21. The use of the DNA sequence according to any one of claims 1 to 4 for the preparation of a medicament useful in a gene therapy method of diseases related to immune maturation and regulation of immune response towards self and nonself, such as autoimmune polyendocrinopathy-  
10 candidiasis-ectodermal dystrophy (APECED).

22. The use of the DNA sequence according to any one of claims 1 to 4 in the treatment of diseases related to immune maturation and regulation of immune response towards self and nonself, such as autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED).

15 23. Reagents reacting with the DNA sequence according to any one of claims 1 to 4 or the protein of any one of the claims 5 to 8 or with reagents reacting therewith.

24. Reagents according to claim 23, characterized in that they are antibodies.

# Human chromosome 21









FIG. 2

3/10




FIG. 3

4/10




FIG. 4


5/10

AIR-1:	299	CAVCRDGGELICCDGCPRAFHACLSPPLREIPSGTWRCSSC	340
AIR-1:	434	.G..G..TDVLR.TH.AA...WR.HF.AGTSR.GTGL..R..	475
Mi-2	: 373	.E..QQ...I.L..T....Y.MV..D.DMEKA.E.K.S.PH.	414
Mi-2	: 452	.R..K.....T..SSY.IH..N...P...N.E.L.PR.	493
TIF1	: 791	....QN.....EK..KV...S.HV.T.TNF...E.I.TF.	832
<u>consensus</u>		C C C C H C C C	

FIG. 5

6/10

1 2 3 4 5 6



09/508658







FIG. 7B

FIG. 7A

**FIG. 7C**



9/10

**FIG. 8A****FIG. 8B**

09/508658 10/29/00






Table 1. Demographic characteristics of the study population	
Age (years)	50.0 ± 10.0
Gender	
Male	50.0%
Female	50.0%
Education (years)	12.0 ± 2.0
Marital status	
Married	80.0%
Single	20.0%
Occupation	
Professional	30.0%
Managerial	20.0%
Technical	10.0%
Service	20.0%
Unemployed	20.0%
Income (USD/month)	1,500.0 ± 500.0
Health status	
Good	70.0%
Fair	20.0%
Poor	10.0%

Attorney's Docket No. U 012653-9**PATENT****COMBINED DECLARATION AND POWER OF ATTORNEY**(ORIGINAL, DESIGN, NATIONAL STAGE OF PCT, SUPPLEMENTAL, DIVISIONAL,  
CONTINUATION OR C-I-P)

As a below named inventor, I hereby declare that:

**TYPE OF DECLARATION**

This declaration is of the following type:

(check one applicable item below)

- ☐ original.  
☐ design.  
☐ supplemental.

**NOTE** If the declaration is for an International Application being filed as a divisional, continuation or continuation-in-part application, do not check next item; check appropriate one of last three items.

- ☒ national stage of PCT.

**NOTE** If one of the following 3 items apply, then complete and also attach ADDED PAGES FOR DIVISIONAL, CONTINUATION OR C-I-P

- ☐ divisional.  
☐ continuation.  
☐ continuation-in-part (C-I-P).

**INVENTORSHIP IDENTIFICATION**

**WARNING:** If the inventors are each not the inventors of all the claims, an explanation of the facts, including the ownership of all the claims at the time the last claimed invention was made, should be submitted

My residence, post office address and citizenship are as stated below, next to my name. I believe that I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter that is claimed, and for which a patent is sought on the invention entitled:

**TITLE OF INVENTION**

Novel gene defective in apced and its use



## SPECIFICATION IDENTIFICATION

the specification of which:

(complete (a), (b) or (c))

- (a) ☐ is attached hereto.
- (b) ☐ was filed on \_\_\_\_\_, as ☐ Serial No. 0 / \_\_\_\_\_  
or ☐ Express Mail No., as Serial No. not yet known \_\_\_\_\_  
and was amended on \_\_\_\_\_ (if applicable).

NOTE Amendments filed after the original papers are deposited with the PTO that contain new matter are not accorded a filing date by being referred to in the declaration. Accordingly, the amendments involved are those filed with the application papers or, in the case of a supplemental declaration, are those amendments claiming matter not encompassed in the original statement of invention or claims. See 37 CFR 1.67

- (c) ☒ was described and claimed in PCT International Application No. PCT/FI98/00749, filed on 23 Sept. 1998 and as amended under PCT Article 19 on \_\_\_\_\_ (if any).

## ACKNOWLEDGEMENT OF REVIEW OF PAPERS AND DUTY OF CANDOR

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information, which is material to patentability as defined in 37, Code of Federal Regulations, § 1.56,

(also check the following items, if desired)

- ☐ and which is material to the examination of this application, namely, information where there is a substantial likelihood that a reasonable Examiner would consider it important in deciding whether to allow the application to issue as a patent, and
- ☐ in compliance with this duty, there is attached an information disclosure statement, in accordance with 37 CFR 1.98.

## PRIORITY CLAIM (35 U.S.C. § 119(a)-(d))

I hereby claim foreign priority benefits under Title 35, United States Code, § 119(a)-(d) of any foreign application(s) for patent or inventor's certificate or of any PCT international application(s) designating at least one country other than the United States of America listed below and have also identified below any foreign application(s) for patent or inventor's certificate or any PCT international application(s) designating at least one country other than the United States of America filed by me on the same subject matter having a filing date before that of the application(s) of which priority is claimed.

(complete (d) or (e))

- (d) ☐ no such applications have been filed.
- (e) ☒ such applications have been filed as follows.

NOTE Where item (c) is entered above and the International Application which designated the U.S. itself claimed priority check item (e), enter the details below and make the priority claim.

**PRIOR FOREIGN/PCT APPLICATION(S) FILED WITHIN 12 MONTHS  
(6 MONTHS FOR DESIGN) PRIOR TO THIS APPLICATION  
AND ANY PRIORITY CLAIMS UNDER 35 U.S.C. § 119(a)-(d)**

COUNTRY (OR INDICATE IF PCT)	APPLICATION NUMBER	DATE OF FILING (day, month, year)	PRIORITY CLAIMED UNDER 37 USC 119
FI	973762	23 Sept. 1997	<input checked="" type="checkbox"/> YES    NO <input type="checkbox"/>
			<input type="checkbox"/> YES    NO <input type="checkbox"/>
			<input type="checkbox"/> YES    NO <input type="checkbox"/>
			<input type="checkbox"/> YES    NO <input type="checkbox"/>
			<input type="checkbox"/> YES    NO <input type="checkbox"/>

**CLAIM FOR BENEFIT OF PRIOR U.S. PROVISIONAL APPLICATION(S)**  
(34 U.S.C. § 119(e))

I hereby claim the benefit under Title 35, United States Code, § 119(e) of any United States provisional application(s) listed below:

PROVISIONAL APPLICATION NUMBER

FILING DATE

\_\_\_\_ / \_\_\_\_\_  
\_\_\_\_ / \_\_\_\_\_  
\_\_\_\_ / \_\_\_\_\_

\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_

**CLAIM FOR BENEFIT OF EARLIER US/PCT APPLICATION(S)  
UNDER 35 U.S.C. 120**

- ☐ The claim for the benefit of any such applications are set forth in the attached ADDED PAGES TO COMBINED DECLARATION AND POWER OF ATTORNEY FOR DIVISIONAL, CONTINUATION OR CONTINUATION-IN PART (C-I-P) APPLICATION.

09508658-110300

7

**ALL FOREIGN APPLICATION(S), IF ANY, FILED MORE THAN 12 MONTHS  
(6 MONTHS FOR DESIGN) PRIOR TO THIS U.S. APPLICATION**

NOTE. If the application filed more than 12 months from the filing date of this application is a PCT filing forming the basis for this application entering the United States as (1) the national stage, or (2) a continuation, divisional, or continuation-in-part, then also complete **ADDED PAGES TO COMBINED DECLARATION AND POWER OF ATTORNEY FOR DIVISIONAL, CONTINUATION OR C-I-P APPLICATION** for benefit of the prior U.S. or PCT application(s) under 35 U.S.C. § 120.

**POWER OF ATTORNEY**

I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith.

(list name and registration number)

PAUL B. WEST, 18947	PETER D. GALLOWAY, 27885
JOSEPH H. HANDELMAN, 26179	IAN C. BAILLIE, 24090
JOHN RICHARDS, 31053	THOMAS F. PETERSON, 24790
JOHN J. CHRYSTAL, 26360	RICHARD P. BERG, 28145
RICHARD J. STREIT, 25765	JULIAN H. COHEN, 20302
ALAN K. ROBERTS, 17777	WILLIAM R. EVANS, 25858
S. DELVALLE GOLDSMITH, 14383	JANET I. CORD, 33778
	CLIFFORD J. MASS, 30086

(check the following item, if applicable)

- ☐ Attached, as part of this declaration and power of attorney, is the authorization of the above-named attorney(s) to accept and follow instructions from my representative(s)

SEND CORRESPONDENCE TO

DIRECT TELEPHONE CALLS TO.  
(Name and telephone number)

LADAS & PARRY  
26 WEST 61ST STREET  
NEW YORK, NEW YORK 10023

(212)708-1930

**DECLARATION**

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

(check proper boxes) for any of the following added page(s)  
that form a part of this declaration)

☒ **Signature** for fourth and subsequent joint inventors. Number of pages added  
2

. . .

☐ **Signature** by administrator(trnx), executor(trnx) or legal representative for deceased or incapacitated inventor. Number of pages added \_\_\_\_\_

. . .

☐ **Signature** for inventor who refuses to sign or cannot be reached by person authorized under 37 CFR 1.47. Number of pages added \_\_\_\_\_

. . .

☐ Added page for **signature** by one joint inventor on behalf of deceased inventor(s) where legal representative cannot be appointed in time. (37 CFR 1.47)

. . .

☐ Added pages to combined declaration and power of attorney for divisional, continuation, or continuation-in-part (C-I-P) application.

☐ Number of pages added \_\_\_\_\_

. . .

☐ Authorization of attorney(s) to accept and follow instructions from representative.

. . .

(if no further pages form a part of this Declaration,  
then end this Declaration with this page and check the following item)

☐ This declaration ends with this page.

0930659 140200

6

# SIGNATURE(S)

NOTE Carefully indicate the family (or last) name, as it should appear on the filing receipt and all other documents.

Full name of sole or first inventor

1-00

Kai Krohn  
(GIVEN NAME) (MIDDLE INITIAL OR NAME) FAMILY (OR LAST NAME)

Inventor's signature

Date 2.3.2000 Country of Citizenship Finland

Residence Salmentaukie 751 FI

Post Office Address 36450 SALMENTAUKA

Full name of second joint inventor, if any

2-00

Maarit Heino  
(GIVEN NAME) (MIDDLE INITIAL OR NAME) FAMILY (OR LAST NAME)

Inventor's signature

Date 2.3.2000 Country of Citizenship Finland

Residence Kaskitie 61 94 FI

Post Office Address 33540 TA

Full name of third joint inventor, if any

3-00

Pärt Peterson  
(GIVEN NAME) (MIDDLE INITIAL OR NAME) FAMILY (OR LAST NAME)

Inventor's signature

Date 2.3.2000 Country of Citizenship Estonia

Residence Kaskitie 13 F 61 FI

Post Office Address 33540 TAMPERE

0050858-110300

→

Attorney's Docket No. U 012653-9

ADDED PAGE TO COMBINED DECLARATION AND POWER OF ATTORNEY FOR SIGNATURE BY FOURTH AND SUBSEQUENT INVENTORS

Full name of fourth joint inventor, if any

4-a  
Hamish S Scott  
GIVEN NAME MIDDLE INITIAL OR NAME FAMILY (OR LAST NAME)  
Inventor's signature Hamish Scott  
Date 8/10/00 Country of Citizenship Australia  
Residence 15 Kew-Hill Gardens AUX  
Post Office Address BRUNSWICK WEST  
VICTORIA 3057 AUSTRALIA

Full name of fifth joint inventor, if any

Stylianios  Antonarakis  
GIVEN NAME MIDDLE INITIAL OR NAME FAMILY (OR LAST NAME)  
Inventor's signature \_\_\_\_\_  
Date \_\_\_\_\_ Country of Citizenship US/Greece  
Residence \_\_\_\_\_  
Post Office Address \_\_\_\_\_

Full name of sixth joint inventor, if any

Maria D Lalioti  
GIVEN NAME MIDDLE INITIAL OR NAME FAMILY (OR LAST NAME)  
Inventor's signature Maria D Lalioti  
Date 10-10-00 Country of Citizenship GREECE  
Residence 79 STOCKDALE PLACE  
Post Office Address EDGBASTON BIRMINGHAM  
B15 3XH UK



29 H06 FUS

Attorney's Docket No. U 012653-9

ADDED PAGE TO COMBINED DECLARATION AND POWER OF ATTORNEY FOR SIGNATURE BY FOURTH AND SUBSEQUENT INVENTORS

4-00 Full name of fourth joint inventor, if any  
Hamish Scott  
GIVEN NAME MIDDLE INITIAL OR NAME FAMILY (OR LAST NAME)  
Inventor's signature \_\_\_\_\_  
Date \_\_\_\_\_ Country of Citizenship Australia  
Residence \_\_\_\_\_  
Post Office Address \_\_\_\_\_

5-00 Full name of fifth joint inventor, if any  
Stylianios E. Antonarakis  
GIVEN NAME MIDDLE INITIAL OR NAME FAMILY (OR LAST NAME)  
Inventor's signature S.E. Antonarakis  
Date 29 Sep 00 Country of Citizenship US/Greece  
Residence 28 Blvd des Philosophes CH  
Post Office Address 1205 Geneva  
SWITZERLAND

6-00 Full name of sixth joint inventor, if any  
Maria D. Lalioti  
GIVEN NAME MIDDLE INITIAL OR NAME FAMILY (OR LAST NAME)  
Inventor's signature Popovich  
Date 18-10-00 Country of Citizenship GREECE  
Residence 79 STOCKDALE PL. EDGBASTON CH  
Post Office Address BIRMINGHAM UK B15 3XH

## SIGNATURE(S)

NOTE: Carefully indicate the family (or last) name, as it should appear on the filing receipt and all other documents.

Full name of sole or first inventor

Kai

(GIVEN NAME)

(MIDDLE INITIAL OR NAME)

Krohn

(FAMILY (OR LAST NAME))

Inventor's signature \_\_\_\_\_

Date \_\_\_\_\_ Country of Citizenship Finland

Residence \_\_\_\_\_

Post Office Address \_\_\_\_\_

Full name of second joint inventor, if any

Maarit

(GIVEN NAME)

(MIDDLE INITIAL OR NAME)

Heino

(FAMILY (OR LAST NAME))

Inventor's signature \_\_\_\_\_

Date \_\_\_\_\_ Country of Citizenship Finland

Residence \_\_\_\_\_

Post Office Address \_\_\_\_\_

Full name of third joint inventor, if any

Pärt

(GIVEN NAME)

(MIDDLE INITIAL OR NAME)

Peterson

(FAMILY (OR LAST NAME))

Inventor's signature \_\_\_\_\_

Date \_\_\_\_\_ Country of Citizenship Estonia

Residence \_\_\_\_\_

Post Office Address \_\_\_\_\_

(check proper box(es) for any of the following added page(s)  
that form a part of this declaration)

☒ **Signature** for fourth and subsequent joint inventors. Number of pages added  
2

. . .

☐ **Signature** by administrator(trix), executor(trix) or legal representative for de-  
ceased or incapacitated inventor. Number of pages added \_\_\_\_\_

. . .

☐ **Signature** for inventor who refuses to sign or cannot be reached by person  
authorized under 37 CFR 1.47. Number of pages added \_\_\_\_\_

. . .

☐ Added page for **signature** by one joint inventor on behalf of deceased inventor(s)  
where legal representative cannot be appointed in time. (37 CFR 1.47)

. . .

☐ Added pages to combined declaration and power of attorney for divisional,  
continuation, or continuation-in-part (C-I-P) application.

☐ Number of pages added \_\_\_\_\_

. . .

☐ Authorization of attorney(s) to accept and follow instructions from representative.

. . .

(if no further pages form a part of this Declaration,  
then end this Declaration with this page and check the following item)

☐ This declaration ends with this page.

2

Attorney's Docket No. \_\_\_\_\_

ADDED PAGE TO COMBINED DECLARATION AND POWER OF  
ATTORNEY FOR SIGNATURE BY FOURTH AND SUBSEQUENT INVENTORS

Full name of 7th joint inventor, if any

<u>Nobuyoshi</u>		<u>Shimizu</u>
<small>GIVEN NAME</small>	<small>MIDDLE INITIAL OR NAME</small>	<small>FAMILY (OR LAST NAME)</small>

Inventor's signature \_\_\_\_\_

Date \_\_\_\_\_ Country of Citizenship Japan

Residence \_\_\_\_\_

Post Office Address \_\_\_\_\_

Full name of 8th joint inventor, if any

<u>Jun</u>		<u>Kudoh</u>
<small>GIVEN NAME</small>	<small>MIDDLE INITIAL OR NAME</small>	<small>FAMILY (OR LAST NAME)</small>

Inventor's signature \_\_\_\_\_

Date \_\_\_\_\_ Country of Citizenship Japan

Residence \_\_\_\_\_

Post Office Address \_\_\_\_\_

Full name of 9th joint inventor, if any

_____	_____	_____
<small>GIVEN NAME</small>	<small>MIDDLE INITIAL OR NAME</small>	<small>FAMILY (OR LAST NAME)</small>

Inventor's signature \_\_\_\_\_

Date \_\_\_\_\_ Country of Citizenship \_\_\_\_\_

Residence \_\_\_\_\_

Post Office Address \_\_\_\_\_

Attorney's Docket No. U 012653-9**PATENT****COMBINED DECLARATION AND POWER OF ATTORNEY**(ORIGINAL, DESIGN, NATIONAL STAGE OF PCT, SUPPLEMENTAL, DIVISIONAL,  
CONTINUATION OR C-I-P)

As a below named inventor, I hereby declare that:

**TYPE OF DECLARATION**

This declaration is of the following type:

(check one applicable item below)

- ☐ original.  
☐ design.  
☐ supplemental.

NOTE If the declaration is for an International Application being filed as a divisional, continuation or continuation-in-part application, do not check next item; check appropriate one of last three items.

- ☒ national stage of PCT.

NOTE If one of the following 3 items apply, then complete and also attach ADDED PAGES FOR DIVISIONAL, CONTINUATION OR C-I-P

- ☐ divisional.  
☐ continuation.  
☐ continuation-in-part (C-I-P).

**INVENTORSHIP IDENTIFICATION**

**WARNING:** If the inventors are each not the inventors of all the claims, an explanation of the facts, including the ownership of all the claims at the time the last claimed invention was made, should be submitted.

My residence, post office address and citizenship are as stated below, next to my name. I believe that I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter that is claimed, and for which a patent is sought on the invention entitled:

**TITLE OF INVENTION**

Novel gene defective in apced and its use



## SPECIFICATION IDENTIFICATION

the specification of which:

(complete (a), (b) or (c))

- (a) ☐ is attached hereto.
- (b) ☐ was filed on \_\_\_\_\_ as ☐ Serial No. 0 / \_\_\_\_\_  
or ☐ Express Mail No., as Serial No. not yet known \_\_\_\_\_  
and was amended on \_\_\_\_\_ (if applicable).

**NOTE** Amendments filed after the original papers are deposited with the PTO that contain new matter are not accorded a filing date by being referred to in the declaration. Accordingly, the amendments involved are those filed with the application papers or, in the case of a supplemental declaration, are those amendments claiming matter not encompassed in the original statement of invention or claims. See 37 CFR 1.67

- (c) ☒ was described and claimed in PCT International Application No. PCT/FI98/00749, filed on 23 Sept. 1998 and as amended under PCT Article 19 on \_\_\_\_\_ (if any).

## ACKNOWLEDGEMENT OF REVIEW OF PAPERS AND DUTY OF CANDOR

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information, which is material to patentability as defined in 37, Code of Federal Regulations, § 1.56,

(also check the following items, if desired)

- ☐ and which is material to the examination of this application, namely, information where there is a substantial likelihood that a reasonable Examiner would consider it important in deciding whether to allow the application to issue as a patent, and
- ☐ in compliance with this duty, there is attached an information disclosure statement, in accordance with 37 CFR 1.98.

## PRIORITY CLAIM (35 U.S.C. § 119(a)-(d))

I hereby claim foreign priority benefits under Title 35, United States Code, § 119(a)-(d) of any foreign application(s) for patent or inventor's certificate or of any PCT international application(s) designating at least one country other than the United States of America listed below and have also identified below any foreign application(s) for patent or inventor's certificate or any PCT international application(s) designating at least one country other than the United States of America filed by me on the same subject matter having a filing date before that of the application(s) of which priority is claimed.

(complete (d) or (e))

- (d) ☐ no such applications have been filed.
- (e) ☒ such applications have been filed as follows.

**NOTE** Where item (c) is entered above and the International Application which designated the U.S. itself claimed priority check item (e), enter the details below and make the priority claim.

Table 1. Demographic characteristics of the study population	
Age (years)	Mean (SD)
Male	55.2 (10.5)
Female	56.8 (11.2)
Marital status	
Married	68.5%
Single	31.5%
Education level	
High school or above	72.3%
Below high school	27.7%
Occupation	
Professional	15.2%
Managerial	12.8%
Technical	18.5%
Service	22.1%
Unemployed	31.4%
Income (USD/month)	
< 1000	12.5%
1000-2000	25.3%
2000-3000	38.7%
> 3000	23.5%
Health insurance	
Yes	85.6%
No	14.4%
Comorbidities	
Hypertension	45.2%
Diabetes	32.1%
Cholesterol	28.9%
Smoking status	
Current smoker	18.7%
Former smoker	22.3%
Non-smoker	59.0%

**CLAIM FOR BENEFIT OF PRIOR U.S. PROVISIONAL APPLICATION(S)**  
(34 U.S.C. § 119(e))

PROVISIONAL APPLICATION NUMBER	FILING DATE
_____ / _____	_____
_____ / _____	_____
_____ / _____	_____

2 The claim for the benefit of any such applications are set forth in the  
3 attached ADDED PAGES TO COMBINED DECLARATION AND POWER OF  
4 ATTORNEY FOR DIVISIONAL, CONTINUATION OR CONTINUATION-IN-  
5 PART (C-I-P) APPLICATION.

(Declaration and Power of Attorney [1-1]—page 3 of 6)

**ALL FOREIGN APPLICATION(S), IF ANY, FILED MORE THAN 12 MONTHS  
(6 MONTHS FOR DESIGN) PRIOR TO THIS U.S. APPLICATION**

---

---

*NOTE. If the application filed more than 12 months from the filing date of this application is a PCT filing forming the basis for this application entering the United States as (1) the national stage, or (2) a continuation, divisional, or continuation-in-part, then also complete ADDED PAGES TO COMBINED DECLARATION AND POWER OF ATTORNEY FOR DIVISIONAL, CONTINUATION OR C-I-P APPLICATION for benefit of the prior U.S. or PCT application(s) under 35 U.S.C. § 120.*

**POWER OF ATTORNEY**

I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith.

*(list name and registration number)*

PAUL B. WEST, 18947  
JOSEPH H. HANDELMAN, 26179  
JOHN RICHARDS, 31053  
JOHN J. CHRYSTAL, 26360  
RICHARD J. STREIT, 25765  
ALAN K. ROBERTS, 17777  
S. DELVALLE GOLDSMITH, 14383

PETER D. GALLOWAY, 27885  
LAIN C. BAILLIE, 24090  
THOMAS F. PETERSON, 24790  
RICHARD P. BERG, 28145  
JULIAN H. COHEN, 20302  
WILLIAM R. EVANS, 25858  
JANET I. CORD, 33778  
CLIFFORD J. MASS, 30086

*(check the following item, if applicable)*

- ☐ Attached, as part of this declaration and power of attorney, is the authorization of the above-named attorney(s) to accept and follow instructions from my representative(s).

SEND CORRESPONDENCE TO

LADAS & PARRY  
26 WEST 61ST STREET  
NEW YORK, NEW YORK 10023

DIRECT TELEPHONE CALLS TO.  
*(Name and telephone number)*

(212)708-1930

**DECLARATION**

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.



Attorney's Docket No. U 012653-9**PATENT****COMBINED DECLARATION AND POWER OF ATTORNEY**(ORIGINAL, DESIGN, NATIONAL STAGE OF PCT, SUPPLEMENTAL, DIVISIONAL,  
CONTINUATION OR C-I-P)

As a below named inventor, I hereby declare that:

**TYPE OF DECLARATION**

This declaration is of the following type:

(check one applicable item below)

- ☐ original.  
☐ design.  
☐ supplemental.

**NOTE** If the declaration is for an International Application being filed as a divisional, continuation or continuation-in-part application, do not check next item; check appropriate one of last three items.

- ☒ national stage of PCT.

**NOTE** If one of the following 3 items apply, then complete and also attach **ADDED PAGES FOR DIVISIONAL, CONTINUATION OR C-I-P**

- ☐ divisional.  
☐ continuation.  
☐ continuation-in-part (C-I-P).

**INVENTORSHIP IDENTIFICATION**

**WARNING:** If the inventors are each not the inventors of all the claims, an explanation of the facts, including the ownership of all the claims at the time the last claimed invention was made, should be submitted.

My residence, post office address and citizenship are as stated below, next to my name. I believe that I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter that is claimed, and for which a patent is sought on the invention entitled:

**TITLE OF INVENTION**

Novel gene defective in apced and its use



## SPECIFICATION IDENTIFICATION

the specification of which:

(complete (a), (b) or (c))

- (a) ☐ is attached hereto.
- (b) ☐ was filed on \_\_\_\_\_, as ☐ Serial No. 0 / \_\_\_\_\_  
or ☐ Express Mail No., as Serial No. not yet known \_\_\_\_\_  
and was amended on \_\_\_\_\_ (if applicable).

**NOTE** Amendments filed after the original papers are deposited with the PTO that contain new matter are not accorded a filing date by being referred to in the declaration. Accordingly, the amendments involved are those filed with the application papers or, in the case of a supplemental declaration, are those amendments claiming matter not encompassed in the original statement of invention or claims. See 37 CFR 1.67.

- (c) ☒ was described and claimed in PCT International Application No. PCT/F198/00749, filed on 23 Sept. 1998 and as amended under PCT Article 19 on \_\_\_\_\_ (if any).

## ACKNOWLEDGEMENT OF REVIEW OF PAPERS AND DUTY OF CANDOR

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information, which is material to patentability as defined in 37, Code of Federal Regulations, § 1.56,

(also check the following items, if desired)

- ☐ and which is material to the examination of this application, namely, information where there is a substantial likelihood that a reasonable Examiner would consider it important in deciding whether to allow the application to issue as a patent, and
- ☐ in compliance with this duty, there is attached an information disclosure statement, in accordance with 37 CFR 1.98.

## PRIORITY CLAIM (35 U.S.C. § 119(a)-(d))

I hereby claim foreign priority benefits under Title 35, United States Code, § 119(a)-(d) of any foreign application(s) for patent or inventor's certificate or of any PCT international application(s) designating at least one country other than the United States of America listed below and have also identified below any foreign application(s) for patent or inventor's certificate or any PCT international application(s) designating at least one country other than the United States of America filed by me on the same subject matter having a filing date before that of the application(s) of which priority is claimed.

(complete (d) or (e))

- (d) ☐ no such applications have been filed.
- (e) ☒ such applications have been filed as follows.

**NOTE** Where item (c) is entered above and the International Application which designated the U.S. itself claimed priority check item (e), enter the details below and make the priority claim.

**CLAIM FOR BENEFIT OF PRIOR U.S. PROVISIONAL APPLICATION(S)**  
(34 U.S.C. § 119(e))

PROVISIONAL APPLICATION NUMBER	FILING DATE
_____ / _____	_____
_____ / _____	_____
_____ / _____	_____

11 The claim for the benefit of any such applications are set forth in the  
12 attached ADDED PAGES TO COMBINED DECLARATION AND POWER OF  
13 ATTORNEY FOR DIVISIONAL, CONTINUATION OR CONTINUATION-IN-  
14 PART (C-I-P) APPLICATION.

**ALL FOREIGN APPLICATION(S), IF ANY, FILED MORE THAN 12 MONTHS  
(6 MONTHS FOR DESIGN) PRIOR TO THIS U.S. APPLICATION**

NOTE. If the application filed more than 12 months from the filing date of this application is a PCT filing forming the basis for this application entering the United States as (1) the national stage, or (2) a continuation, divisional, or continuation-in-part, then also complete **ADDED PAGES TO COMBINED DECLARATION AND POWER OF ATTORNEY FOR DIVISIONAL, CONTINUATION OR C-I-P APPLICATION** for benefit of the prior U.S. or PCT application(s) under 35 U.S.C. § 120.

**POWER OF ATTORNEY**

I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith.

(list name and registration number)

PAUL B. WEST, 18947

JOSEPH H. HANDELMAN, 26179

JOHN RICHARDS, 31053

JOHN J. CHRYSTAL, 26360

RICHARD J. STREIT, 25765

ALAN K. ROBERTS, 17777

S. DELVALLE GOLDSMITH, 14383

PETER D. GALLOWAY, 27885

IAIN C. BAILLIE, 24090

THOMAS F. PETERSON, 24790

RICHARD P. BERG, 28145

JULIAN H. COHEN, 20302

WILLIAM R. EVANS, 25858

JANET I. CORD, 33778

CLIFFORD J. MASS, 30086

(check the following item, if applicable)

- ☐ Attached, as part of this declaration and power of attorney, is the authorization of the above-named attorney(s) to accept and follow instructions from my representative(s)

SEND CORRESPONDENCE TO

DIRECT TELEPHONE CALLS TO.  
(Name and telephone number)

LADAS & PARRY

26 WEST 61ST STREET

NEW YORK, NEW YORK 10023

(212) 708-1930

**DECLARATION**

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

**SIGNATURE(S)**

NOTE: Carefully indicate the family (or last) name, as it should appear on the filing receipt and all other documents.

Full name of sole or first inventor

Kai  Krohn  
(GIVEN NAME) (MIDDLE INITIAL OR NAME) FAMILY (OR LAST NAME)

Inventor's signature \_\_\_\_\_

Date \_\_\_\_\_ Country of Citizenship Finland

Residence \_\_\_\_\_

Post Office Address \_\_\_\_\_

\_\_\_\_\_  
[Signature of second joint inventor, if any]

Full name of second joint inventor, if any

Maarit  Heino  
(GIVEN NAME) (MIDDLE INITIAL OR NAME) FAMILY (OR LAST NAME)

Inventor's signature \_\_\_\_\_

Date \_\_\_\_\_ Country of Citizenship Finland

Residence \_\_\_\_\_

Post Office Address \_\_\_\_\_

\_\_\_\_\_  
[Signature of third joint inventor, if any]

Full name of third joint inventor, if any

Pärt  Peterson  
(GIVEN NAME) (MIDDLE INITIAL OR NAME) FAMILY (OR LAST NAME)

Inventor's signature \_\_\_\_\_

Date \_\_\_\_\_ Country of Citizenship Estonia

Residence \_\_\_\_\_

Post Office Address \_\_\_\_\_

0050658 110300

(check proper box(es) for any of the following added page(s)  
that form a part of this declaration)

☒ **Signature** for fourth and subsequent joint inventors. Number of pages added  
2

. . .

☐ **Signature** by administrator(tnx), executor(tnx) or legal representative for deceased or incapacitated inventor. Number of pages added \_\_\_\_\_

. . .

☐ **Signature** for inventor who refuses to sign or cannot be reached by person authorized under 37 CFR 1.47. Number of pages added \_\_\_\_\_

. . .

☐ Added page for **signature** by one joint inventor on behalf of deceased inventor(s) where legal representative cannot be appointed in time. (37 CFR 1.47)

. . .

☐ Added pages to combined declaration and power of attorney for divisional, continuation, or continuation-in-part (C-I-P) application.

☐ Number of pages added \_\_\_\_\_

. . .

☐ Authorization of attorney(s) to accept and follow instructions from representative.

. . .

(if no further pages form a part of this Declaration,  
then end this Declaration with this page and check the following item)

☐ This declaration ends with this page.

2

Attorney's Docket No. \_\_\_\_\_

**ADDED PAGE TO COMBINED DECLARATION AND POWER OF  
ATTORNEY FOR SIGNATURE BY FOURTH AND SUBSEQUENT INVENTORS**

Full name of fourth joint inventor, if any

<u>Hamish</u>	<u></u>	<u>Scott</u>
<small>GIVEN NAME</small>	<small>MIDDLE INITIAL OR NAME</small>	<small>FAMILY (OR LAST NAME)</small>

Inventor's signature \_\_\_\_\_

Date \_\_\_\_\_ Country of Citizenship Australia

Residence \_\_\_\_\_

Post Office Address \_\_\_\_\_

Full name of fifth joint inventor, if any

<u>Stylianios</u>	<u></u>	<u>Antonarakis</u>
<small>GIVEN NAME</small>	<small>MIDDLE INITIAL OR NAME</small>	<small>FAMILY (OR LAST NAME)</small>

Inventor's signature \_\_\_\_\_

Date \_\_\_\_\_ Country of Citizenship US/Greece

Residence \_\_\_\_\_

Post Office Address \_\_\_\_\_

Full name of sixth joint inventor, if any

<u>Maria</u>	<u></u>	<u>Lalioti</u>
<small>GIVEN NAME</small>	<small>MIDDLE INITIAL OR NAME</small>	<small>FAMILY (OR LAST NAME)</small>

Inventor's signature \_\_\_\_\_

Date \_\_\_\_\_ Country of Citizenship \_\_\_\_\_

Residence \_\_\_\_\_

Post Office Address \_\_\_\_\_

09500658 110300

Attorney's Docket No. \_\_\_\_\_

ADDED PAGE TO COMBINED DECLARATION AND POWER OF  
ATTORNEY FOR SIGNATURE BY FOURTH AND SUBSEQUENT INVENTORS

Full name of 7th joint inventor, if any

7-00 Nobuyoshi

GIVEN NAME

MIDDLE INITIAL OR NAME

Shimizu

FAMILY (OR LAST NAME)

Inventor's signature \_\_\_\_\_

Date \_\_\_\_\_ Country of Citizenship Japan

Residence \_\_\_\_\_

Post Office Address \_\_\_\_\_

Full name of 8th joint inventor, if any

8-00 Jun

GIVEN NAME

MIDDLE INITIAL OR NAME

Kudoh

FAMILY (OR LAST NAME)

Inventor's signature \_\_\_\_\_

Date \_\_\_\_\_ Country of Citizenship Japan

Residence \_\_\_\_\_

Post Office Address \_\_\_\_\_

Full name of 9th joint inventor, if any

GIVEN NAME

MIDDLE INITIAL OR NAME

FAMILY (OR LAST NAME)

Inventor's signature \_\_\_\_\_

Date \_\_\_\_\_ Country of Citizenship \_\_\_\_\_

Residence \_\_\_\_\_

Post Office Address \_\_\_\_\_



